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SUMMARY
Primary open angle glaucoma (P.O.A.G.) is a major cause of 
blindness throughout the world. This disease is characterised by raised 
intraocular pressure (I.O.P.) leading to progressive vision loss. 
Topical beta blockers decrease aqueous production and therefore lower
I.O.P. How beta blockers decrease aqueous production is not known. It 
is presumed they exert their I.O.P. lowering effect by binding to 
ciliary process beta-adrenoceptors.
The purpose of this study was to determine whether beta- 
adrenoceptors exist in pigmented ciliary process; to determine the 
subtype (Beta-1 or Beta-2) of receptor present in the ciliary processes; 
to determine which beta blocker binds most potently to the receptors in 
vitro and finally to determine whether specific beta blockers inhibit 
aqueous production and lower I.O.P.
The results of the radioligand binding portion of this study 
indicate that beta-adrenoceptors do exist in pigmented animal ciliary 
processes (Bmax = 98.0 (+ 7.30) fmol/mg protein, KD = .363 (+ 0.01) nM) 
and they are of the Beta-2 subtype. The Beta-2 blockers LI 32-468, ICI 
118551 and IPS 339 bind potently to these receptors (mean values 2.91 
x 10"^M, 4.65 x 10~®M, 8.16 x 10"®M respectively).
The results of I.O.P. recovery rate experiments (aqueous humour 
index) indicate that Beta-2 specific blockers significantly inhibit 
rabbit aqueous humour production. The results of studies on rabbits 
with glaucoma revealed that Beta-2 blockers lower intra-ocular pressure.
XV
In conclusion, this is the first study implicating Beta-2 adreno­
ceptors as the major receptor subtype controlling aqueous production and
I.O.P. Furthermore, the results of this study indicate that Beta-2 
blockers may prove to be a valuable new treatment for patients with 
glaucoma.
XVI
INTRODUCTION
I . Primary Open Angle Glaucoma and Beta-Adrenoceptors
Primary open angle glaucoma (P.O.A.G.) is a major cause of 
blindness throughout the world (Ghafour et al., 1984). The disease is 
characterised by progressive vision loss, abnormally high intraocular 
pressure (I.O.P.) and glaucomatous optic neuropathy probably due to 
failure of circulation at the optic nerve head (Hayreh, 1972). The
abnormally high I.O.P. is due to inadequate drainage of aqueous humour 
through the trabecular meshwork (Grant, 1958, Ashton, 1960; TripathI, 
1969; Krasnov, 1972; Segawa, 1979; Moses et al, 1981, Fine, 1981).
Intra-ocular pressure is directly related to both aqueous 
production and outflow (Shields, 1982). An increase in outflow 
resistance increases I.O.P., while a decrease in aqueous production 
lowers I.O.P. It is believed that lowering I.O.P. prevents glaucomatous 
optic neuropathy and visual fifiLed loss (Podos, 1980; McLaughlin et al, 
1985).
Topical beta blockers decrease aqueous production and lower I.O.P. 
(Higgins and Brubaker, 1980; Zimmerman and Kaufman, 1977). The obvious 
assumption is that these drug, induced effects are modulated by beta- 
adrenoceptors. This view however has been challenged (Smith, 1987; 
Langham, 1979; Kriegelstein, 1980; Strempel, 1982). There is little 
evidence of beta-adrenoceptors in ciliary process epithelium (which is 
the major aqueous secreting tissue (see later)) and little evidence as 
to whether the receptors are of the beta-1 or beta-2 subtype.
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The work reported in this thesis supports the view that beta- 
adrenoceptors control I.O.P. Specifically we report:
1) That beta-adrenoceptors exist in pigmented ciliary processes.
2) That B 2 receptors are the major subtype.
3) That 1*2 blockers inhibit aqueous production in normal animal
eyes.
4) That 1*2 blockery lower I.O.P. in rabbits with glaucoma.
2
II. The Sympathetic Nervous System and Adrenoceptors
A) General Review
The human efferent autonomic nervous system is divided into two 
divisions:
1) The parasympathetic nervous system.
2) The sympathetic nervous system.
The sympathetic nuclei are mainly found in the hypothalmus and 
medulla oblongata. Descending fibres pass down the spinal cord to 
innervate preganglionic cell bodies located in the intermedio-lateral 
column of the thoracolumbar segments of the spinal cord (T-^  - L^).
These preganglionic neurons synapse with post-ganglionic neurons in the 
sympathetic trunk or other specialized collateral ganglia. The post 
ganglionic neurons terminate in nerve endings at responsive organs. 
Most post-ganglionic sympathetic fibres release catecholamines from 
their nerve endings. These fibres are designated adrenergic neurons. 
Adrenergic neurons elicit adrenergic responses by liberating 
catecholamines that bind to end organ receptors. The end organ 
receptors for adrenergic transmitters are known as adrenoceptors.
In vivo adrenergic responses are ellicited by;
1) Catecholamine transmitters (especially noradrenaline).
2) Circulating catecholamines from the adrenal medulla 
(Adrenaline).
3) Topical systemic or parenteral administration of 
catecholamines or related compounds.
In vitro adrenergic responses are ellicited by exogenous 
catecholamines in denervated or innervated preparations. This indicates
3
that nerve endings per se are not required for a response. As indicated 
above the adrenoceptor is the specialized part of the effector cell 
through which catecholamines and adrenergic compounds act to evoke a 
characteristic response.
Briefly, the biosynthetic pathway for catecholamines is as follows 
(Blaschko, 1973):
L-Tyrosine
^  Tyrosine hydroxylase
L-DOPA
L-Dopa decarboxylase
Dopamine
- Dopamine B - hydroxylase
N/
Noradrenaline
Pheny1ethano1amine N -methy11rans feras e
V
Adrenaline
In most sympathetic ganglionic fibres this synthesis stops with 
noradrenaline production, while in the adrenal medulla it continues on 
to adrenaline. In some central nervous system (C.N.S.) pathways 
synthesis stops at dopamine. Dopamine, noradrenaline and adrenaline are 
liberated as neurotransmitters in the C.N.S. (Livett, 1973; Fuxe et al., 
1975; Ungerstedt, 1971).
Adrenoceptors are divided into alpha and beta subtypes (Ahlquist, 
1948). Beta-adrenoceptors have been further subdivided by Land et al., 
into Beta-1 and Beta-2 adrenoceptors (Land et al., 1967). Alpha 
receptors are classified as alpha-1 and alpha-2 receptors (Hoffman and
4
Lefkowitz, 1980).
Table 1 illustrates the autonomic responses. It shows that 
adrenergic responses are mediated by alpha and beta-adrenoceptors.
Beta adrenoceptors ellicit intracellular responses by activating a 
membrane bound enzyme, adenylate cyclase. This results in the 
intracellular production of adenosine 3'-5'-monophosphate (see later).
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Table 1:
Autonomic Responses
1/ \
Parasympathetic Sympathetic
Cholinergic
Cholinergic
Adrenergic
Alpha Beta
ocl oc2 B,
Autonomic responses, transmitters and receptors.
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Figure 1 illustrates the events that occur at the synapse of a 
typical sympathetic neuron and its effector cell. It shows pre- 
synaptic and post-synaptic receptor sites.
Alpha receptors and beta receptors on the post-synaptic membrane 
elicit responses when stimulated by noradrenaline or circulating 
adrenaline. Pre-synaptic alpha£ receptors are believed by some workers 
to inhibit noradrenaline release from the nerve terminal (Hoffman and 
Lefkowitz, 1980; Lees, 1981), while pre-synaptic beta-2 receptor 
stimulation may cause neurotransmitter release (Majewski and Rand, 
1981).
Noradrenaline is released from vesicles in the nerve terminal by a 
process of exocytosis initiated by the influx of calcium ions during 
each nerve action potential (Langer and Hicks, 1984; Lees, 1981). Once 
released noradrenaline diffuses into the synaptic cleft to stimulate 
alpha or beta receptors on the effector cell membrane. Depending on the 
frequency of discharge of the nerve action potential and the junctional 
width, presynaptic alpha-2 receptors may reduce further release of 
noradrenaline (negative feedback) (Hoffman and Lefkowitz, 1980).
It is believed by some workers that adrenaline may be taken up from 
the circulation into the sympathetic nerve terminal vesicles for release 
with the neurotransmitter noradrenaline. Nerve action potentials and 
pre-synaptic beta-2 receptor stimulation by circulating adrenaline may 
therefore cause both adrenaline and noradrenaline release into the 
synaptic cleft (Majewski and Rand, 1981).
Figure 2 summarizes this positive feedback mechanism in diagramatic 
form (Majewski and Rand, 1981). Blockade of beta receptors at the pre
7
and post synaptic junctions not only prevents catecholamines from 
stimulating the effector cell but also may decrease the release of 
transmitter agents. Pre-junctional beta-2 receptor blockade is believed 
by some workers to be of some importance in the mechanism of action of 
beta blockers in hypertension (Majewski and Rand, 1981). Prejunctional 
dopamine (DA-2) and muscarinic receptors are believed to lead to 
inhibition of noradrenaline release when stimulated (Langer and Hicks, 
1984).
Figure 3 illustrates the fate of norepinephrine after binding to 
receptor sites. It can be taken up by the presynaptic neuron (uptake 
1) , or be taken up and metabolized by the post-synaptic cell (uptake 2), 
finally norepinephrine can simply diffuse away into the extracellular 
compartment.
Table 2 is a schematic representation of the range of action of 
agonists and antagonists at adrenoceptor sites. Timolol, pindolol and 
propranolol are shown to block beta-1 and beta-2 receptor sites, while 
atenolol, metoprolol and practolol mainly block beta-1 receptor sites. 
IPS-339, ICI-118551 and LI 32-468 are all beta-2 adrenoceptor blockers.
Betaxolol, not shown on this table is also a potent beta-1 blocker. 
Isoprenaline stimulates both beta-1 and beta-2 receptors while 
salbutamol stimulates beta-2 receptors. Phenylephrine is an alpha-1 
stimulant.
8
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B) The Sympathetic nervous system and Intra-ocular pressure
Considerable evidence exists to suggest that the sympathetic 
nervous system plays a significant but complex role regulating eyefluid 
(aqueous humour) production and intra-ocular pressure. A short review 
of the evidence appears below.
1. Adrenergic drugs (both stimulants and blockers) influence 
intraocular pressure by affecting aqueous humour production (Thomas et 
al., 1981; Yorio, 1985; Brubaker, 1986; Podos, 1980 and Neufeld, 1979).
2. Sympathetic nerve fibres innervate the ciliary processes and 
lie in intimate contact with the ciliary epithelium (Ehinger, 1964). 
Histochemical work shows that most of the adrenergic neurones in the 
ciliary processes lie in a sub-epithelial plexus. Adrenergic 
innervation to the blood vessels supplying the ciliary processes is 
limited (Ehinger, 1964).
3. Stimulation of the cervical sympathetic chain affects both 
uveal blood flow and aqueous humour formation (Best et al., 1972; Aim, 
1977).
4. Cyclic AMP is produced by the ciliary processes on adrenergic 
stimulation (Neufeld, 1973). Cyclic AMP is not produced by the ciliary 
processes in the presence of beta blockers (Neufeld, 1979).
5. Aqueous humour contains all three catecholamines (Trope and 
Rumley, 1985; Cooper et al., 1984; Trope et al., 1987).
The role of the sympathetic nervous system on aqueous production 
and I.O.P. control will be further discussed in detail later.
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Ill) Review of Beta-Adrenoceptors
A. Beta-adrenoceptor: Structure and Size
Beta adrenoceptors are presently believed to be membrane bound 
glycoproteins (Lefkowitz et al., 1984; Stadel et al., 1981). The size 
of the beta receptor varies according to tissue, species and methodology 
used to detect it. The two methods usually used to study receptor 
structure are affinity chromatography and photoaffinity labeling 
(Lefkowitz et al., 1984). Other techniques however, have been described 
(Venter and Fraser, 1983). Mammalian beta-adrenergic receptors are 
reported to consist of a single glycoprotein with a molecular mass of 
58,000 to 64,000 daltons (Lefkowitz et al., 1984; Venter and Fraser, 
1985).
B. Beta-adrenoceptors and the Hormone-Sensitive Adenylate-Cyclase System 
Beta-adrenoceptors are functionally coupled to an enzyme known as
adenylate cyclase. Binding of beta stimulants to the beta-adrenoceptor 
adenylate cyclase complex accelerates the rate of Adenosine 3'-5' cyclic 
monophosphate (cAMP) synthesis. cAMP mediates and activates many 
intracellular reactions. All tissues with beta-adrenoceptors react by 
producing cAMP (Sutherland and Rail, 1980). Alpha-1 adrenoceptors are 
not clearly linked to the adenylate cyclase system while alpha- 2  
adrenoceptors inhibit adenylate cyclase activity (Michael et al., 1982).
Figure 4 illustrates the schematic model and components of the 
receptor hormone sensitive adenylate cyclase system (Stiles et al. , 
1984). Adrenergic receptors can stimulate or inhibit this system. Beta 
receptors are stimulatory in action whereas Alpha-2 and muscarinic
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receptors are inhibitory. An important second component of the system 
is the catalytic moj&ty of the adenylate cyclase system (C). This 
mo/e.ty converts adenosine 5'-triphosphate (ATP) to adenosine 3':5'- 
cyclic monophosphate (cAMP). Details of the molecular structure of 
adenylate cyclase remain elusive (Ross, and Gilman, 1980). The third 
important component of this system is the guanine nucleotide regulatory 
protein (N protein, also called N, G/F or G) (Rodbell, 1980). Adenylate 
cyclase requires guanine nucleotides in vitro for activation. The 
regulatory protein is present in a stimulatory and inhibitory form. The 
stimulatory N protein is composed of j subunits known as alpha . beta 
subunits. The inhibitory N protein is believed to be similar to the 
stimulatory protein except that the alpha subunit has a different size. 
The alpha subunit contains the guanosine-5'-triphosphate (GTP) binding 
site (Stiles et al., 1984).
The N protein involved in coupling stimulatory beta-adrenergic 
receptors contains a guanosine triphosphatase (GTPase) that stops each 
cycle of adenylate cyclase activation by hydrolyzing GTP to guanosine- 
5'-diphosphate (GDP) (Lefkowitz et al., 1985) (Cassel, and Selinger,
1974). Cholera Toxin activates cyclic AMP by inactivating the GTPase 
portion of the alpha subunit of the Ns protein. This inactivation 
inhibits the physiological turn off mechanism for adenylate cyclase and 
makes GTP an irreversible activator i.e. the Ns protein is unable to 
stop adenylate cyclase activation (Cassell and Pfeuffer, 1978).
Figure 5 further elucidates this complex reaction (Stiles et al., 
1984) . The initial event is the binding of agonist H to receptor R to 
form a low affinity H.R. complex. This binary complex then forms a high
14
MEMBRANE
GDP
GTP
GTP
GDP
FIG.4  Schematic model of hormone-sensitive adenylate cyclase system. ATP, adenosine 
triphosphate; C, catalytic unit; cAMP, adenosine 3':5’-cyciic phosphate; GDP, guanosine 5-d i­
phosphate; GTP, guanosine 5'-triphosphate; H, hormone; i, inhibitor!'; N, guanine nucleotide 
regulatory component; R, receptor, s, stimulatory.
t
GTP
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Beta Adrenergic Nucleotide Regulatory Adenylate Cyclase
Receptor Cycle Protein Cycle Catalytic Moiety Cycle
FIG.5. Working model for adenylate cyclAse regulation by /3-adrenergic agonists and gua­
nosine 5-triphosphate (GTP). H, 0-adrenergic agonist; R, 0-adrenergic receptor; N, guanine 
nucleotide regulatory protein; C, catalytic moiety of adenylate cyclase.
Above two figures produced from Stiles et al., 1984 with permission from"
the editor.
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affinity tertiary complex with the N protein HRN. A change occurs in
the N protein such that its subunits dissociate. GTP binds to the
alpha-subunit. This N-GTP unit complexes with the catalytic moeity of
adenylate cyclase (C) thereby activating and forming the Ng^pC complex
which is assumed to be the active form of the enzyme. The GTPase moeity
on the N protein rapidly cleaves GTP to GDP thereby destabilizing the 
n
Ngpp complex reverting its activity to base level. If hormone is 
removed or its antagonist is added, the entire chain of events is 
blocked because there is no impetus to the formation of the crucial 
intermediory HRN (Ross, 1977; Stiles et al., 1984; Lefkowitz, 1984).
The intracellular biological effects of cAMP are mediated
protein kinase. (Greengard, McAfee and Kebabian, 1972). 
cAMP is metabolized by cyclic nucleotide phosphodiesterase to 5 'AMP and 
inorganic phosphate. (Thompson and Applemon, 1971).
C) Modulation of Beta-adrenoceptor adenylate cyclase activity
Two types of mechanisms exist to regulate beta-adrenoceptor 
function namely; 1) Homologous regulation, 2) Heterologous regulation.
Homologous regulation is the term sometimes used to denote the 
regulation of numbers or concentration of receptors by hormones or drugs 
that usually combine with the receptor (Su and Harden, 1980), e.g.,
adrenaline and propranolol. The term heterologous regulation is used to 
denote receptor regulation by drugs or hormones that do not ordinarily 
bind to beta-receptors, for example steroids and prostaglandins.
1) Down Regulation
Homologous and heterologous regulation are believed to be able, at
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least in the short term, to cause translocation of receptors from the 
plasma membrane to the intracellular compartment (Stiles et al., 1984) 
(Chuang and Costa, 1979) (Stadel et al., 1983) (Su et al., 1980). Short 
term decrease in receptor numbers from agonist stimulation is thought to 
be due to this endocytic process (Stadel et al., 1983). Once
internalized, the receptors seem to reside in vesicles. On removal of 
the agonist, receptor numbers increase probably via two mechanisms, 
namely a recycling process and in some cell lines new protein synthesis 
(Doss, Perkins and Harden, 1981). In this latter situation it is 
believed that the internalized receptors are degraded (Stiles et al., 
1984).
In addition to this rapid down- regulation of beta-adrenoceptor 
density, long term exposure to adrenergic drugs in vivo induces a 
gradual alteration in receptor density that persists for several weeks 
(Vitulani and Salser, 1975). Stiles et al and others have suggested 
that the effects observed in receptor numbers after agonist use over the 
long term may be controlled by beta-receptor gene transcription 
affecting both the rate of receptor synthesis and perhaps degradation as 
well (Stiles et al, 1984) (Chiu, 1978) (Dax, Partilla and Gregerman, 
1981).
Another method of regulating beta-adrenoceptor function involves 
receptor uncoupling to the adenylate cyclase system. It is believed 
that there maybe a number of different kinds of processes that lead to 
uncoupling (Su et al., 1980) (Harden et al., 1980). Phosphorylation 
reactions may be involved in this uncoupling reaction (Stiles et al., 
1984). In some cases, cAMP is possibly a mediator. In heterologous
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desensitization N-protein alterations may also occur which could be 
responsible for this effect. To date little information exists on 
receptor uncoupling (Stiles et al., 1984).
In summary multiple mechanisms are involved in modulation of 
catecholamines induced desensitization of adenylate cyclase. Agonists 
induce down regulation by promoting receptor internalization and also 
sequestration away from the other components of the adenylate cyclase 
system. The receptors are then degraded or recycled to the cell 
surface. In other cases the receptors can become functionally uncoupled 
from adenylate cyclase.
2. Up-Regulation
Long-term reduction of circulating catecholamines or adrenergic 
denervation induces "up regulation" i.e. an increase in receptor 
numbers, e.g. after adrenalectomy there is a marked increase in both 
number of liver beta-adrenoceptors and adenylate cyclase activity (Wolfe 
et al. , 1976). The exact mechanism controlling this phenomenon is not
clear. Up regulation has however been confirmed by a variety of workers 
(Kajiyana and Acgawa, 1980) (Glaubiger and Lefkowitz, 1977) (Glaubiger 
et al. , 1978) (Tenner et al., 1982). Whether up regulation is
responsible for the well known supersensitivity that occurs after 
propranolol withdrawal however is uncertain (Boudoulas et al., 1977; 
Stiles et al., 1984; Kennedy and Connelly, 1982). Upregulation of beta 
receptors has been suggested as a reason for the slight decrease in
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efficacy of beta blocker eye drops in patients with glaucoma (Boger, 
1979).
Heterologous beta-adrenoceptor regulation does occur. Thyroid 
hormones for example regulate beta-receptor density and possibly 
affinity as well. Hyperthyroidism is associated with an increase in 
receptor numbers, while hypothyroidism is associated with a decrease in 
receptor numbers. The exact mechanism responsible for thyroid 
regulation of the receptor numbers remains unclear (Stiles et al., 
1984).
D) Receptor Identification (Burt, 1985)
A binding site is identified as a receptor for a drug or 
transmitter if it meets certain criteria. The binding site should
1 ) be present in numbers and have high affinity 
(saturability).
2 ) have acceptable kinetics
3) be stereoselective and bind drugs in a predictable rank order 
of potency.
4) be found only where receptors are expected (distribution)
5) be occupied by drugs effective at the receptor at 
concentrations in proportion to those needed to produce a 
biological response (Pharmacology).
6 ) be destroyed by high temperature (temperature sensitivity) and 
influenced by other factors, (for example ph and ions) (Burt, 
1985; Motulsky and Insel, 1982).
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1 . Saturability
To determine whether receptors exist in a tissue there must be a 
minimal requirement of a finite number of binding sites of fairly high 
affinity (i.e. with a dissociate/) constant in the nanomolar range or 
lower).
a) Saturation:
Indicative of receptors is the phenomenon of saturation, that is as 
one adds increasing concentrations of radioligand, binding to receptor 
sites increases to a point until all sites are occupied. Thereafter 
additional concentration of hot ligand binds only to non-receptor sites. 
Binding to non receptor sites is known as non-specific binding. Total
binding is determined for each concentration of radioligand. Total
binding is determined by measuring the radiation emitted from each
sample. It represents the amount of radioligand bound to both receptor
sites and non-specific binding sites (Motulusky and Insel, 1982).
It is essential to determine exactly how much non-specific binding 
occurs. This is done by incubating samples ("Blanks") of the 
radioligand membrane preparation together with a fixed concentration of 
a non radioactive drug which is known to bind only to the receptor 
sites, e.g. 1 uM (-) propranolol for beta-adrenoceptors (Mukherjee et 
al., 1975). This "cold ligand" competes with radioactive ligand for the 
receptor sites and displaces radioligand off these sites. The residual 
amount of radio-activity bound non-specifically to membrane preparations 
is then measured. Specific binding is determined for each concentration 
of radioligand from the formula: Specific binding = Total binding
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Non-specific binding (Motulusky and Insel, 1982). Non-specific binding 
is therefore potentially infinite while specific binding 
characteristically shows saturation (Burt, 1985).
b) Number and Affinity of Sites
It is well known that too large a number of receptors with low 
affinity suggests binding is not to a receptor. Receptor density (Bmax) 
in brain for example falls in the range of 1 - 100 pMoles/g weight of 
tissue (Burt, 1985). Rat cerebral cortex beta adrenoceptors have a Bmax 
of 12 pmol/g and a Kp of 0.1 nM. Rat heart beta-adrenoceptors have a 
Bmax of 5-10 pMol/g with a of 1-2 nM.
Mathematical analysis of saturability data, allows one to determine 
both affinity and receptor numbers and will be considered in the next 
chapter. Graphical analysis of binding data is often performed using 
micro-computer assisted programs e.g. ligand (Munson and Rodbard, 1980) 
or ligand (Applesoft) (Jackson and Edwards, 1984). For this study, we 
used an Apple II micro-processor with a program developed by Clark et 
al. (Clark et al., 1983).
c) Competition by Non-Radioactive drugs
In the presence of a finite number of bindings sites, addition of 
enough non-radioactive drug molecules of the same or different drug, 
results in competition with radioactive molecules for occupation of the 
limited number of receptor binding sites. This competition, also known 
as displacement, reduces the number of radioactive bound molecules. The 
Pharmacology of binding refers to the effectiveness of different drugs 
acting as competing agents. Some form of competition experiment using
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one or more drugs is often among the initial experiments used when 
trying to identify a receptor.
2. Kinetics
Binding should occur with speed and should be rapidly reversible. 
The equations describing simple binding reactions predict that the 
equilibrium dissociation constant should be given by the ratio of the 
rate constant for dissociation to the rate constant for association 
(Lefkowitz, 1976; Insel and Stoolman, 1978). Kinetic studies are an 
important aspect of receptor identification and will be considered 
further in the next chapter.
3. Distribution
On detecting a high affinity saturable binding site, further 
experiments should be performed on tissues from different areas of the 
body to ensure the results are in keeping with known data on that 
specific receptor type. It is important to note however that large 
differences in receptor numbers or characteristics exist in various 
species and sub-cellular fractions. Receptors should also be of the 
type innervated by the appropriate nervous system.
4. Pharmacology (Burt, 1985)
It is important to relate the data derived from binding experiments 
to data derived from biological responses (Pharmacology). Drugs that 
are effective in mimicking or blocking the effects of a neurotransmitt^j; 
should be shown to compete for binding at low concentrations whereas 
ineffective drugs should compete at high concentrations if at all.
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a) Stereospecificity
A most useful pharmacological criterion for identifing receptor 
binding is stereospecificity which may involve either the radioligand 
itself or non-radioactive drugs used as competing agents. Many 
responses of biological systems distinguish between stereoisomers. 
Clearly, binding to receptors mediating these responses should be the 
same (Synder, Pasternak and Pert, 1975; Aurbach et al., 1974; Motulusky 
and Insel, 1982).
b) Choice of Blank
With multiple binding sites a critical factor in identifying the 
receptor of interest involves using the correct choice of blank. Use of 
a large excess of the same drug, in non-radioactive form is often 
inappropriate as it competes for all classes of binding sites. Rather a 
very carefully chosen excess of the neurotransmitter itself is often a 
good choice, although other highly specific drugs are reasonable 
alternatives e.g. 1 uM (-) propranolol for beta adrenoceptors (Mukher, 
J. et al., 1975). In many cases the concentration of drug used as the 
blank (non-specific binding) in saturation experiments is 1 0 0  times the 
concentration needed to inhibit specific binding by 50% (IC^q).
c) Agonist and Antagonists
Apparent binding affinities typically differ according to whether 
an agonist or antagonist is used as radioactive ligand. A variety of 
explanation exists for this effect including preferential binding of 
agonist and antagonists to different receptor conformational states, 
desensitized receptor binding to agonists and multiple classes of
23
agonist binding. A theory of spare receptors exists to explain the 
increased biological effect seen with agonists compared with the 
agonists in vitro binding potency (Takeyasu, 1979). The net result of 
these considerations is that only the affinities of antagonists 
competing for antagonist binding regularly match biological potencies 
(Burt, 1985).
d) Additivity with Blank
When 2 or more drugs are available as blanks an important criterion
for identifying the portion of total binding representing receptor
binding involves showing that maximally effective concentrations of both
drugs compete for the receptor sites whether they are added individually 
or in combination.
Other aspects of pharmacology of binding include non-competitive 
agents, use of antibodies to identify receptors and response of the 
tissue under study to radioactive ligand used in a binding experiment 
(Burt, 1985).
5) Other Important Points
a) Tissue Linearity
Tissue linearity is important in binding studies to demonstrate the 
absence of artifacts such as receptor or ligand degradation during 
incubation and/or unrecognized endogenous ligand binding. Although a 
slight degree of downward curvature in a graph plotting binding against 
added tissue is unlikely to lead to wrong receptor identification, it 
will yield incorrect or ambiguous values for such parameters as density 
of binding sites. It is therefore desirable to find conditions that
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give linearity of binding with tissue concentrations, even if this 
entails one or more membrane purification steps and a lower recovery of 
receptors. The unusual condition of upward curvature in tissue 
linearity graphs, which is equally undesirable, may indicate an 
inappropriate blank or loss of binding sites during the separation from 
free ligand (Burt, 1985).
b) Temp. Dependence 
Temperatures of greater than 40 °C decrease or destroy receptor 
binding. Binding at higher temperatures suggests the possibility of a 
covalent chemical reaction of the radioactive ligand or breakdown 
product rather than reversible receptor binding.
c) Effect of ph and Ions
Receptors operate under physiological conditions usually at pH 7.4. 
Extremes of pH decrease or eliminate binding as the receptor structure 
disrupts.
Effects of ions are less predictable on binding but can aid 
receptor identification when the effects of receptor activation on ionic 
conductances are known and there is close or direct coupling between the 
receptor binding site and "ionic conduction modulation" (Burt, 1985).
d) Identity of Bound Radioactivity 
If a new radioligand is used it is important to demonstrate that 
most or all bound radioactivity still represents the original ligand. 
Verification of the identity of bound radioactivity remains an important
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part of receptor identification.
Final proof of receptor identification requires purification of the 
binding site and demonstration that adding the purified sites to model 
membrane systems results in these systems gaining receptor properties 
(Burt, 1985).
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E) LIGAND RECEPTOR BINDING EXPERIMENTS: Practical and Theoretical
Considerations.
1) Binding Experiments (Bennet and Yamamura, 1985)
a) General Mathematical Considerations
Ligand receptor binding studies follow kinetics similar to classic 
enzyme substrate interactions. For reversible ligand receptor 
interactions where 
[L] = concentration of ligand 
[R] = concentration of occupied receptors 
[LR] = concentration of ligand receptor complex
This formula represents a reversible binding phenomenon, with a, b 
and c representing stoichiometry of the reaction. At equilibrium, the 
rate of the forward reaction equals the rate of the reverse reaction
The equilibrium binding constant can be therefore defined as an 
association binding constant (K^)
a[L] + b[R] c[L.R. ]
(1 )
namely; K+ 1  [L]a [R]b - K_x [LR]C (2)
K+1 [LR]C
K.x [L]a [R]b
(3)
or as a
dissociation binding constant (Kp)
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K_! [L] [R]'
Kd ----------------  (4)
M-lK+ 1  [LR]°
Therefore to determine the equilibrium dissociation constant for a 
reversible reaction requires that the experiment be performed under 
steady state conditions.
An important property of ligand receptor interaction is 
saturability; that is only a finite number of specific receptors exist 
per unit of tissue. This maximum number of specific receptors is 
designated Bmax
[“ ] + [R 1 " Bmax 
multiply by [L]
[LR] [L] + [L] [R] - Bmax [L]
[LR] [L] + [LR] [L] [R] - Bmax [L]
[LR]
Substitute equation 4 with a = b = c = 1. This gives
[LR] <[L] + Kjj) - Bmax [L]
Bmax W
[ LR]-----------  (5)
[L] + Kd
which is the classic law of mass action for enzyme substrate
interactions adapted to ligand - receptor interactions.
If we now define [LR] as bound ligand = B, and L as free ligand = F,
from equation 5
B F max
B =■— ----
F + Kd
BF + BKD = BmQVF max
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divide by F
B + B KD
=  B,max
F
Transferring fields
B B,max B
(6)
F
which is the Scatchard Equation (Scatchard, 1949). Thus knowing the 
concentration of ligand bound and free at equilibrium allows the 
determination of both the equilibrium binding constant and the
maximum number of binding sites Bmax (Bennett and Yamamura, 1985).
b) Separating Bound from free ligand 
Filtration and centrifugation are the major techniques used to 
separate bound from free ligand. Other techniques used usually on 
soluble binding sites include dialysis, column chromatography, 
precipitation of ligand receptor complex and adsorption of free ligand.
During washing, i.e. the process used to separate bound from free 
ligand, some ligand will dissociate from the complex. This rate of 
dissociation of the ligand receptor complex is the major constraint on 
separation techniques. Loss of binding due to dissociation usually 
increases linearly through the first half-life for dissociation of the 
receptor ligand complex. To avoid losing more than approximately 10% 
of bound ligand it is recognized that the separation procedure should be
complete in less than 0.15 tj /^2 (assuming an association rate constant
6-1 -1of 10 M" Sec" ). Because it is desirable to wash the ligand receptor
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complex as thoroughly as possible to remove free unbound ligand, the 
time of washing (which forms part of the total separation time, i.e. the 
total time in which the ligand receptor complex can dissociate during 
separation) plays a crucial role in increasing non-specific bound ratio 
or decreasing the specific bound ratio. As indicated studies have 
determined that 0.15 t ^ 2  a desirable maximum separation time. The 
approximate upper limit for separation time has been calculated for 
various steady state dissociation binding constants, for example a of
-  f t  -  O
10 M has an allowable separation time of only 0.01 sec. 10 M has an
-10allowable separation time of 10 sec. 10 M has an allowable separation
-11time of 17 mins. 10 M has a separation time of 2.9 hours.
1) Filtration
Filtration techniques allow for rapid and efficient separation of
bound from free ligand especially for particulate receptor studies. As
indicated above filtration works only for ligand receptor binding
-  8processes with steady state dissociation constant (K^) values of + 1 0 "
M or less due to time constraints.
A potential disadvantage of filtration is non-specific binding of 
radioligand to the filter material (Pasternak and Snljder, 1975). Thus 
it is important to select a filter that minimumfl.y binds radioligand or 
to include anti-adsorbants that minim' ize this non-specific binding. 
Filtration was used during this project.
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2) Centrifugation
This method is useful for particular ligand-receptor studies under 
two conditions 1 ) where rapid dissociation occurs especially in 
association with low affinity receptor binding (10"^ M or greater), 2)
where non-specific binding to filters cannot be reduced.
This technique involves surface washing of the pellet. This is 
less efficient than filtration techniques in separating bound ligand 
from free ligand. Unbound radioligand is often trapped in the pellet 
water space (Streeten, 1982). With centrifugation rapid careful rinsing 
of the tube and pellet with ice-cold buffer is performed to remove as 
much unbound radioligand as possible without allowing the rinsing buffer 
to remain in contact with the pellet for more than a few seconds as this 
may result in dissociation of the ligand receptor complex or else 
disrupts the integrity of the pellet with mechanical loss of ligand 
receptor complex. Conical microcentrifuge tubes containing
dibuty lphthalate - dinonylphthalate oil mixtures are used for such 
procedures. If mixed in a 3:2 ratio the oil is denser than isotonic or 
hypotonic aqueous buffers but less dense than for example brain 
preparations. A small quantity of oil is placed at the bottom of the 
tube and the tissue preparation in buffer containing ligand is layered 
on top. After incubation and washing samples are centrifuged in 
microcentrifuge tubes. The tip of the microcentrifuge tube containing 
the pellet in oil is then cut off and bound radioactivity measured. 
This procedure allows for rapid separation of the particulate bound 
matter from unbound and incubation buffer. The disadvantage as 
previously mentioned is related to insufficient washing of the pellet.
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Also, very lipophilic radioligands can potentially diffuse into the oil 
layer giving elevated inconsistant non-specific binding.
3) Equilibrium Dialysis
This technique is suitable for receptors with low affinity ligands 
(10”^ M or greater) and thus very rapid dissociation rates. This 
technique involves the use of small dialysis cells of less than 1  ml 
volume (separated by semi-permiable membranes). Rapid equilibration of 
radioligands occurs across the semi-permiable membrane between the 
receptor and the buffer sides of the dialysis cell. A major 
disadvantage of the dialysis technique is the small difference in 
radioactive counts usually found between the receptor and the buffer 
side of the dialysis membrane. Large amounts of receptor protein must 
be added to one side of the dialysis chamber to achieve significant 
binding. It is also necessary to determine if the dialysis membrane 
itself contributes to radioligand binding (Bennett and Yamamura, 1985).
4) Gel Filtration Chromatography
This is a sensitive but tedious method of detecting bound 
radioligand in solubilized or physiologically soluble receptor 
preparations. There are 2 methods presently used both performed at low 
temperatures to retard receptor ligand dissociation (Bennett and 
Yamamura, 1985).
Gel filtration techniques have been used to study soluble 
cytoplasmic steroid hormones from brain and other tissues. The major 
limiting constraint is the dissociation rate of the ligand-receptor 
complex as it passes through the column. Also, the resin bed offers the
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possibility of non-specific binding of radioligand, a condition that 
must be ruled out.
5) Precipitation of ligand-receptor complex and adsorption of free
ligand.
The precipitation technique depends on a decrease in solubility of 
large proteins resulting from the addition of structural perturbing 
agents, e.g. ammonium sulfate, salts acids or polyethylene glycol. 
Successful studies using this technique include solubilized insulin, 
adrenergic, and dopamine receptors.
The adsorption of free ligand technique uses the selective 
adsorption of unbound radioligand to a slurry of inert support such as 
talc or charcoal. The inert support is often coated with a carbohydrate 
polymer (dextran). Small unbound molecules rapidly penetrate the dextran 
shell and are bound by the inert support, whereas large ligand receptor 
complexes are excluded from access to this adsorbent. The adsorbent is 
isolated by centrifugation or filtration and the amount of unbound 
ligand is measured. The difference between total radioligand and the 
unbound ligand adsorbed to the support represents the concentration of 
bound ligand (Bennett and Yamamura, 1985).
6 ) Non-Specific Binding: General Points (Bennett and Yamamura, 1985)
As previously indicated specific binding is considered as the
difference between total binding and the binding that occurs in the 
presence of an excess concentration of unlabeled ligand. At this point 
non-specific binding may be composed of 1) true non-specific binding to 
the tissue, that is ligand not bound to receptors, 2) free radioligand
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not effectively washed away, 3) non-specific binding to separation 
materials such as filters.
It is necessary to wash the preparations to get rid of free 
radioligand. This washing procedure should be optimized by comparing 
various numbers of washing and volumes of washing buffers.
Radiolabelled chemicals used as ligands in receptor-binding studies 
possess the ability to bind non-specifically to both biological and non- 
biological substances, for example, radiolabelled insulin binds to talc 
with affinities in the nanomolar range (Chatrecasas and Hollenberg, 
1976) which is similar to the affinity of insulin for its biological 
receptor. Significant non-specific binding to separation materials can 
often be reduced by including anti-adsorbants in the assay mixture. 
Albumin or collagen are useful for radio-iodtnated peptides and 0- 
catechol for catecholamine binding studies. Anti-adsorbants themselves 
can paradoxically bind significant amounts of radioligand thereby 
reducing available free ligand concentration. As low a concentration of 
anti-adsorbant as possible should be used to lower non-specific 
binding.
It is generally accepted that for binding studies, the competitive 
ligand should be chemically different from the radio-ligand used in the 
study. The use of a disimilar drug that binds potently to the receptors 
increases the probability of obtaining specific receptor binding.
7) Metabolism of radioligand (Bennett and Yamamura, 1985)
Radioligand bound to a receptor or free in solution can be 
metabolized or degraded. Analysis of both bound and free radioligand
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can be performed by both conventional analytical procedures such as 
HPLC, TLC and electrophoresis and by rebinding studies. The principle 
of the chromatographic assays involves comparing the migration of 
radioligand after exposure to the tissue receptor to migration of 
radioligand not exposed to tissue receptor, but analyzed with homologous 
tissue extract. Rebinding studies involve eluting radioligand off the 
receptor site under mild acidic or denaturing conditions and rebinding 
it to a fresh receptor preparation alongside fresh previously unexposed 
radioligand. At equal concentrations of exposed and unexposed 
radioligand the two results should be equal if no metabolism or 
structural changes has taken place to the previously exposed 
radioligand. In addition to the above, the original unbound or free 
(radioligand) can be examined by rebinding studies as well. If the 
ligand is a natural product or a derivative of one (such as 
catecholamines) catabolism can be prevented by reducing the incubation 
temperature or via the addition of various drugs (e.g. MAO). Nonenzymic 
oxidative degradation or light degradation is inhibited by using 
antioxidants or dark incubation using a sodium lamp for visualization.
2) ANALYSIS OF BINDING DATA 
a) Saturation Experiments
To determine the equilibrium dissociation constant and apparent 
number of binding sites (Bmax) for a radioligand and tissue receptor the 
following factors are involved:
1) Various concentrations of radioligand are incubated with fixed 
amounts of tissue.
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2) Bound ligand concentration is determined by filtration or 
other techniques as previously described.
3) The resulting data is analyzed according to the Scatchard 
equation.
1) Dependence of apparent on tissue receptor concentrations.
The apparent can be influenced by receptor concentration.
Estimation of Kp from standard binding isotherms can overestimate the 
magnitude of Kp as the total receptor site concentration (RT) is 
increased. One method to overcome this problem is to perform saturation 
studies using different concentrations of tissue. The results are then 
analyzed by nonlinear least square regression analysis. True can 
then be determined from apparent KD (Bennet and Yamamura, 1985).
2) Scatchard Plots.
The Scatchard equation
B B,max B
F
can also be written as
i m [RT] - [LR]
[L]
This allows for linear transformation of the binding data so that 
Kp and Bmax may be readily determined from standard radioligand 
saturation experiments (Bennet and Yamamura, 1985).
During saturation experiments radioactivity is increased while 
specific activity is held constant. The amount of radioligand 
specifically bound at each radioligand concentration is determined. 
Bound radioligand is expressed as molar concentrations of radioligand 
bound per unit weight of tissue protein and fitted to the Scatchard 
equation. Conventional linear regression techniques are used to 
calculate the line of best fit. After the best fit data is obtained the 
equilibrium dissociation constant (K^) is estimated as the negative 
reciprocal of the slope of the line of best fit. The apparent maximum 
number of binding sites (Bmax) is estimated from the intercept of the 
line with the abscissq . In this thesis a micro-processor was used to 
analyze data from saturation experiments. As previously indicated this 
program was developed by Dr. B. Clark et al (1983) for use on an Apple 
II computer. The major advantage of the Scatchard equation compared to 
other methods of plotting saturation data is that all points from the 
graph are given equal statistical weight. The experimental error in 
determining the major variable, namely bound radioligand is 
mathematically eliminated from the line fitting procedure because the 
variable is present on both ax£s. Assumptions in the derivation and the 
use of Scatchard analysis include the following; 1) the binding process 
must obey simple reversible mass action laws, 2 ) data must be obtained 
at steady state conditions, 3) binding of ligands to receptor site must 
not affect subsequent ligand receptor site interactions, (i.e. no co- 
operativity), 4) ligand and receptor sites must be homogeneous species,
i.e. radiolabelling can cause the ligand to become damaged producing a 
radioligand population composed of heterogenous species with different
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binding affinities to the receptor sites. Heterogenious receptor 
populations also exist. Detection of receptor subtypes requires either 
a ten fold variation in the affinity of the ligand for each receptor 
subtype or, if the radioligand has equal affinity for the subtypes, the
availability of unlabeled drug with at least a 1 0  fold variation in
binding potency at the individual receptor sub-population. 5) 
Concentration of free unbound ligand must be accurately determined. 6 )
Non-specific receptor binding must be properly defined (Bennett and
Yamamura, 1985).
As previously discussed it is best to define non-specific binding 
using chemically dissimilar unlabeled drug to the radioligand at 
concentrations 100-300 times the value. Before attempting a ligand 
saturation study, previously described criteria (radioligand purity and 
metabolism and minimization of non-specific binding) should be 
satisfied. In addition, linearity of radioligand binding with respect 
to the tissue of interest should be demonstrated and the appropriate 
incubation time and temperature to reach the steady state determined. 
With these precautions in mind some workers intially proceed using a 
small concentration of radioligand to obtain a binding constant by 
generating a ligand competition curve. The concentration of unlabelled 
ligand at which the maximum specific binding labeled ligand is inhibited 
by 50% (IC^q) can be taken as a first approximation of the apparent 
equilibrium dissociation binding constant (Kp). A binding saturation 
study can then be done over a range of radioligand concentrations from 
10-20% of this Kp to 4-5 x this value (Bennett and Yamamura, 1985).
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3) Competitive Inhibition Studies
The (the concentration of unlabelled ligand displacing 50% of
specific binding) is used to determine the affinity constant for 
unlabelled drugs (K^).
A fixed concentration of radioligand is incubated with increasing 
concentrations of unlabeled (cold) ligand. The concentration of 
unlabeled ligand displacing 50% of specific radioligand (IC^q) is then 
determined. As the concentration of radioligand [L] utilized in 
inhibition studies is increased, the difference between the IC5 Q of 
unlabeled ligand and the binding affinity constant of unlabeled ligand 
(K^) progressively widens at fixed tissue concentrations according to 
the following equation.
1 + [L]/Kd
This equation applies only to binding where labeled and unlabeled 
ligand interact competitively at the receptor site (Cheng and Prusoff, 
1973).
Jacobs has reported that the concentration of receptor sites in the 
incubation medium can influence the relationship between IC^q and K^. 
IC5 0  - n (Kd + LT + RT - 3/2 LR) (Jacobs et al., 1975).
= Ki + n (LT + RT - 3/2 LR)
LT = total concentration of radiolabeled ligand.
RT = total concentration of receptor sites.
LR = concentration of receptor - radioligand complex formed in the 
absence of unlabeled ligand.
Ki = n Kd
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If LT+ RT is less than the KD then the IC^q approximates K^. In
practice the total number of receptor sites should not exceed 1 0 % of the
Kd for a given radioligand when estimating affinity constants by
competitive displacement.
Computer aided curve fitting programs are available to aid analysis 
of competition data and generation of graphs (McGonigle, 1984). In
this study competition data analysis was performed with a computer aided 
curve fitting program using a mathematical model described by Wenke 
(Wenke, 1971). Details of this program entitled "Reefit" have been
published elsewhere (Clark et al., 1984). All displacement data and 
receptor subtype estimation was analysed using "Recfit" on an Apple II 
microcomputer.
4) Hill Plots (Bennett and Yamamura, 1985)
In some binding studies displacement of radioligand from its 
receptor by unlabeled compounds structurally different from the 
radioligand yields behaviour different from classic mass action laws 
most commonly as negatively cooperative interactions (Hill plot 
significantly less than one). These situations arise primarily in 
instances of a radiolabeled antagonist being displaced by an unlabeled 
agonist or vice-versa. Hill plots are used to detect and quantitate 
such anomalous effects. The Hill equation is:
B [L]n
®max KD + lL]n 
n = Theoretical number of ligand binding sites per receptor molecule.
Kp = Dissociation constant.
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This equation can also be expressed in Log form as:
L°g B
d W  -  B)
n Log[L] - Log Kd
max
or
L°g - f n Log[L] - Log Kd
1 -f
Therefore fitting ligand binding data is straight forward for 
either saturation or competition experiments. Methods to derive the 
above formulae are reviewed by Bennett and Yamamura (Bennett and 
Yamamura, 1985).
5) Rate Constants (Bennett and Yamamura, 1985)
As previously indicated is the equilibrium dissociation constant 
which is the ratio of the binding reactions reverse and forward rate 
constants,
i.e. K 1
Kd ---------
K+1
For this reason it is desirable to estimate the rate constants for 
association (K+^) and dissociation (K_^) so that the binding constant 
derived from saturation data can be compared to the binding constant 
resulting from the ratio of the rate constants (K_^/K+^). If the 
binding reaction under study obeys mass action laws, the binding 
constants derived by these two independent means should be equal within 
experimental error.
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This follows second order kinetics and unimolecular dissociation 
K -i
LR L + R
which follows first order kinetics.
For many neurotransmitter receptor studies to date, the binding 
constants calculated from such a model are usually equal, within error, 
to the binding constants derived from equilibrium saturation studies. 
This is not however always the case.
a) Association Rate Constant (Bennett and Yamamura, 1985)
The simple rate equation for bimolecular association
with L + R equal to free ligand and unoccupied receptor respectively at 
time 0 , x is equal to the amount of each consumed in time t. 
Theoretically equation 8 allows calculation of K+^ for any bimolecular 
binding reaction when L, R and X are known. However, for binding 
studies where 1 0 % or less of the total available ligand is bound at 
equilibrium, K+^ estimated from equation 8 is subject to large error 
because x never exceeds 10% of L. Furthermore the problem is compounded 
because experimentally it is desirable to measure initial ligand 
association rates where ligand - receptor dissociation causes minimal 
error on estimation of K+^. Thus in practice it is not unusual to
d [LR]
K+ 1  [L] [R] (7)
dt
when integrated yields
2.303 Log R [L - x]
(8)
t [L - R] L [R - x]
estimate K+^ based on data where 5% maximum of initial free ligand is 
bound to receptor (Bennet and Yamamura, 1985).
c
More theoretical and experimentally practical methods are used to 
estimate K+ -^. If an initial free ligand concentration of 1/2 the or 
less for that ligand is used and binding data only up to the first half- 
life of association are analysed then at most approximately 1 / 8  of the 
total receptor sites are occupied and [R] can be assumed to be equal to 
Bmax x [Tissue]. Likewise, if the tissue concentration is controlled so 
as to be in zone A behaviour (less than 10% of [L] bound) then [L] does 
not change appreciably and can also be considered constant. Equation 8  
then reduces to
d [LR] K '+ 1
 -------  = (9)
dt
where K '+l " K+1 [L]
Therefore, d [LR] = dt.
To estimate K+ -^ specifically bound ligand is plotted versus time. 
The best line fit through, at most, the first half-life is constructed. 
The slope of this line, is then divided by the initial
concentration of free ligand [L] and receptor ([R] = Bmax x [tissue] ) 
to yield K+ -^.
A second method takes into consideration the contribution of
ligand-receptor dissociation to the eventual reaching of a steady
state. Bound ligand is assayed at various time intervals upto steady
state level (B ).eq
Ln [ Beq/ (Beq - Bfc) ] is plotted versus time where Bfc is the 
amount of specifically bound ligand at time t. The slope of the line
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(K0b s) is related to the association (K+^) and dissociation (K_^) rate 
constants and free ligand concentrations [L] as:
K0bs " K i (Insel and Stoolman, 1978).
K+ 1 ---------- —  (10)
[L]
This equation is valid only when the binding reaction is performed with 
no more than 1 0 % of initial free ligand bound at steady state. 
Estimating K+^ by this method requires knowledge of the dissociation 
rate constant (K_^) as described in the next section.
The use of equation 10 obviates the need for an independent 
determination of Bmax which would be required to use equation 9, also, 
equation 1 0  can be rearranged to:
Kobs - K+1 [LI + K -l-
Thus a plot of KQbs versus [L] should yield a straight line with a 
slope of K+^ and an ordinate intercept of K_-^  if the reaction obeys mass 
action laws and is performed under pseudo-first order conditions with 
respect to [L].
K+^ can be determined from experiments in which both [L] + [R] are 
varied in order to confirm the bimolecular nature of the process. Also, 
K+i can be calculated at various values of [L] from KQb s and the 
independently measured K_^, and compared to values obtained from a plot 
of equation 11. In this way errors in the independent estimation of K_-^  
will become apparent.
In this study K+^ was determined using a computer program developed 
by Steinberg et al (Steinberg et al., 1985) - see below.
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b) Dissociation Rate Constant
The dissociation rate constant (K_-^ ) is estimated by incubating 
radioligand and receptors for a given time period, usually to steady 
state and then infinitely diluting the radioligand concentration. After 
various time intervals specifically bound radioligand is then measured. 
The half-life ^or l°ss °f specifically bound radioligand is
determined from a plot of log [LR] versus time. K_^ is calculated as
0.693/t-jy2* Alternatively the slope of log [LR] versus time multiplied 
by -2.303 = K_x .
Infinite dilution of radioligand can be done in two ways 1)
receptor ligand solutions are incubated to steady state and then diluted 
100 x or more with incubation buffer. Aliquots are then assayed for 
bound radioligand at various times, 2 ) receptor preparations and 
radioligand are incubated to steady state and 1 , 0 0 0  x molar excess of 
unlabeled drug is then added. Receptor-bound radioligand, is assayed at
various time intervals thereafter (Bennet and Yamamura, 1985; Insel and
Stoolman, 1978).
In this study, Kp was determined from kinetic experiments using a 
computer aided curve fitting program developed by Steinberg et al 
(Steinberg et al., 1986). This program analyses data using a
mathematical model described by Moelwyn and Hughes (Moelwyn and Hughes, 
1971).
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3) RADIOLIGAND USED IN THIS STUDY
During this study the radioligand ^^ ^ 1 ] -iodohydroxybenzylpindolol
125[ I]-HYP was used. This ligand emits gamma radiation. Tritiated
3
compounds such as [ H]-dihydroalpranolol (Lefkowitz et al 1974) (beta
radiation emitters) have low specific radioactivity (less than 80
Ci/mmol) (Engel et al., 1981). Because of this low specific activity,
large amounts of tissue in the form of protein are required. In view of
radioactive iodine's high specific activity (1500 - 2000 Ci/mmol) and
125higher affinity (+ 10 times) [ I ] - H Y P  has generally been accepted as a
ligand of choice in beta-receptor studies when only small amounts of
tissue protein are available (Brown et al., 1976). The high specific
activity makes it ideal for use in experiments involving ocular tissues
125as they are not readily available in large amounts. [ I]-
125iodocyanopindolol ([ I]-CYP) also has high specific activity and high
specificity for beta-adrenoceptors (Engel et al., 1981). This newer
radio-ligand is said not to bind to alpha and other non-beta-
T125adrenoceptor sites as may occur with 1 I]-HYP (Engel et al., 1981). 
125[ I]-CYP became available only towards the end of this study and as a 
result preliminary binding data derived with this ligand have not been 
included in this study.
Figure 6 reveals the structure of Pindolol and its two radioactive 
derivatives.
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CHOH *"CH2-NH-CH{CH3)2
PINDOLOL (1965)
OH-
0 -C H 2-CHOH-CH2-NH-C~CH2 —^ OH
125
HYP (1974)
0“CH2”CH0H -CH2“NH-C(CH3)3
125
HN ^  CYP(1979)
CN
FIGURE 6 : Radioligand dc? r i va t. ive 55 of Pindolol
125I-HY P* is a radio-labe 1 led Pindolol 
derivative
125i_cyp is prepared by iodination of 
CYP** as described by Enyol et al 1979.
* HYP is a trivial name Por hydroxy- 
benzylpinJolol
* * CYP is a trivial name for cyano-
p i ndo1ol
IV. Production of aqueous humour by the ciliary processes
As previously indicated I.O.P. depends on aqueous production. If 
aqueous production is inhibited (as occurs with beta-blocker therapy)
I.O.P. drops. This section reviews the theories regarding aqueous 
production.
It is now a well established fact that the ciliary processes are 
the site of aqueous humour production (Cole, 1977) The exact mechanism 
of aqueous humour production however remains controversial, (Cole, 1977; 
Macri et al., 1978; Sears et al., 1986). Most authors agree however
that the epithelium of the ciliary processes and, in particular, the 
inner non-pigmented layer, controls aqueous humour production (Cole, 
1977).
The ciliary processes have a high rate of blood flow (15-25 
ml/min/gram tissue) and a surface area of 6  sq/cm in man. The rate of 
aqueous flow is about 2 ul per minute.
Aqueous production depends on four processes:
A) Sodium potassium activated adenosine triphosphatase [(Na+ :K+ 
ATPase]. Sodium potassium ATPase is present on the basal infoldings of 
membranes of both the outer pigmented and inner non-pigmented ciliary 
epithelial cells (Rich et al., 1980). Sodium potassium ATPase is
considered synoymous with the sodium pump. This sodium pump is 
important as it is sodium transport into the lateral intracellular 
channels that creates the standing osmotic gradient. This gradient 
leads to osmotic waterflow down the channels in a unidirectional manner 
towards the posterior chamber (Nagasubramanian, 1982; Krupin et al.,
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1986). The sodium pump is also important as it establishes an 
electrochemical gradient across the blood epiphelial cell/aqueous humour 
interface.
In vitro studies have shown that ciliary process sodium potassium 
ATPase activity can be inhibited by ouabain and validate (ouabain 
prevents potassium binding to the enzyme at the extracellular surface, 
while var&late acts at the intracellular surface of the membrane bound 
enzyme molecule). The exact relationship between adrenergic drugs used 
to treat glaucoma and sodium potassium ATPase however has not been 
defined. Noradrenergic stimulation can inhibit or excite membrane bound 
sodium potassium ATPase depending on the organ or specie studied 
(Krupin, 1986; Swann, 1983; Lingham and Sen, 1982). It is believed that 
norepinephrine and epinephrine may stimulate sodium potassium ATPase in 
ciliary processes to increase aqueous production but this has as yet to 
be proved (Krupin, 1986).
B) Carbonic anhydrase.
The enzyme carbonic anhydrase is responsible for the catalytic 
hydration and dehydration of carbon dioxide
carbonic
ca2 + OH" ..... ---^ h c o 3"
anhydrase
This enzyme is found in nature as one of four isoenzymes. Type II 
(formerly called type C) is the isoenzyme present in the ciliary 
processes (Kumpulainen, 1983). Carbonic anhydrase is localized both to 
the cell membrane and cytoplasm of pigmented and non-pigmented
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epithelium. Inhibition of this enzyme decreases bicarbonate production 
which inhibits sodium ion movement by 30%. Water entry into the 
posterior chamber is therefore decreased (Maren et al., 1975; Maren,
1984).
Cole has suggested that acetazolamide, a carbonic/anhydrase 
inhibitor reduces short circuit currents across the in vitro ciliary 
body causing a fall in sodium transport. This reduction in short 
circuit current may be due to a drop in intracellular pH (effecting 
sodium potassium ATPase activity) or possibly due to a reduction in the 
amount of sodium entering the cell by way of the hydrogen sodium 
exchange system (Cole, 1966).
C) Adenylate cyclase.
It is now well established that catecholamine sensitive adenylate 
cyclase exists in the ciliary process of animal and man (Waitzman and 
Woods, 1971; Sutherland et al., 1966). Furthermore, it has been shown 
that beta-adrenoceptor stimulation of this tissue results in increased 
cyclic AMP production (Neufeld et al., 1973). Beta-adrenergic 
stimulation also increases aqueous production (Brubaker, 1984). It 
therefore follows that beta-adrenoceptors appear to mediate adenylate 
cyclase control of aqueous production through adenylate cyclase 
stimulation. The exact process involved however, is not well 
understood. In view of the ocular hypotensive effects elicited by 
Forskolin (an adenylate cyclase activator) Sears has suggested that 
increased cAMP activity lowers I.O.P. by stimulating aqueous humour 
outflow through the apices of the ciliary processes. He bases this
50
theory on the embryonic development of the ciliary processes (See 
Discussion). This theory however is controversial particularly inlight 
of recently published data by Brubaker et al., in which no effect on 
intra-ocular pressure or aqueous production was observed in human eyes 
treated with forskolin drops (Brubaker et al., 1986). Nathanson has 
published evidence that beta-adrenoceptor coupled adenylate cyclase 
control of aqueous production is epithelial rather than vascular in 
origin and is mediated by beta-2 receptors (Nathanson, 1981). (See 
Discussion).
D) Ultra-Filtration
Ultra-filtration is also believed to be an important factor 
regulating aqueous humour production (Pederson and Green, 1975). 
Infact, upto 20% of aqueous humour production is believed to be due to 
this process. (Nagasubramanian, 1982). Sears however, believes that 
ultra-filtration has a minor role to play in the production of aqueous 
humour (Sears, 1986).
E) Chloride secretion.
Chloride secretion, dependent on sodium presence, inhibited by 
ouabain and enhanced by intracellular cAMP, has been shown to occur in a 
number of cells across apical and mucosal surfaces (Frizzell et al., 
1979). It is not known whether chloride secretion plays an important 
role in aqueous production but Sears has recently speculated that it may 
(Sears, 1986).
In summary, aqueous humour production seems primarily to be 
controlled by sodium potassium ATPase. Other important factors
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influencing this process include adenylate cyclase, ultra-filtration, 
carbonic anhydrase and perhaps chloride secretion.
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V. History of Adrenergic drugs and intra-ocular pressure
In 1895, Oliver and Schafer isolated adrenaline from the adrenal 
medulla (Oliver et al., 1895). It was not long before it was tested on 
the eye. Darier reported that topical adrenaline both dilated the pupil 
and lowered intra-ocular pressure (Darier, 1900). This effect on intra­
ocular pressure caused much controversy in later trials, as an increase 
in intra-ocular pressure was noted to occur in some patients (MacCallan, 
1903). Undoubtedly this paradoxical increase in pressure was due to 
acute and chronic angle closure glaucoma precipitated by pupillary 
dilatation in patients with narrow angles, a fact not understood until 
the gonioscopy lens was introduced during the 1930's. However, it is 
interesting note that J.H. Parsons in 1903 realized that there was a 
connection between the rise in intra-ocular pressure and pupillary 
dilatation (Parsons, 1903). Wessley attributed adrenaline^s hypotonic 
effect on the eye to vasoconstriction leading to decreased aqueous 
humour production (Wessley, 1900). This theory is still believed by 
some workers to be the primary mechanism of action of adrenaline on 
intra-ocular pressure (Thomas and Epstein, 1981).
Darier's original work stimulated much clinical research into the 
role of adrenaline for the treatment of P.O.A.G. (Darier, 1900; 
MacCallan, 1903; Knapp, 1921; Thomas et al., 1981; Podos, 1980). Today 
topical adrenaline alone or in combination with other drugs is 
considered to be a primary agent for the medical management of primary 
open angle glaucoma (Weinreb, Ritch et al., 1986; Thomas, 1981). 
Adrenaline is now known to increase outflow facility and have complex 
effects on aqueous humour production (See discussion).
53
In 1967, Philips et al., reported the effects of propranolol a non­
specific beta-blocker on intra-ocular pressure after systemic 
administration. These authors reported that both intravenous and oral 
administration of propranolol lowered intra-ocular pressure dramatically 
in patients with POAG (Philips et al., 1967). This report stimulated 
research work directed towards developing a suitable topical beta- 
blocker for use in P.O.A.G. (Bonomi et al., 1975; Eliott et al., 1975; 
Smith et al., 1979; Krieglestein, 1981; Krieglestein et al., 1981).
During 1978, topical (-)timolol maleate a non-specific blocker was 
introduced for the treatment of POAG. This drug is still the most 
widely used non-specific beta-blocker for the treatment of POAG 
(Kaufman, 1980; Novack, 1987). It effectively lowers intra-ocular 
pressure by inhibiting aqueous production and has a b.d. dose schedule. 
Topical (-) timolol maleate does however have significant local and 
systemic side-effects. (Kaufman, 1980). Other beta-blockers recently 
introduced include, 1  -.evobunolol, carteolol and metipranolol, all non­
specific beta-blockers, and betaxolol hydrochloride a beta - 1  specific 
blocker (Duzman et al., 1982; Berrospi and Leibowitz, 1983; Novack,
1987).
Despite over fifteen years of investigation into beta-blockers and 
their role in intra-ocular pressure control, it is still not known 
exactly how these agents work. It is believed by some authors that 
beta-blockers exert their intra-ocular pressure lowering effect by 
binding to beta-adrenoceptors in the epithelial cells of the ciliary 
processes (Thomas et al., 1981; Kaufman, 1980; Neufeld, 1979; Woodward 
et al., 1986). These workers believe that beta-blockers may prevent
active transport, or possibly ultra-filtration of ions and fluid across 
the epithelial barrier (Kaufman, 1980; Neufeld, 1979) (See discussion). 
As previously indicated this theory is controversial as it is not known 
whether beta-adrenoceptors exist in ciliary processes. The next section 
contains a review of work done to determine whether receptor mechanisms 
control aqueous production and I.O.P.
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V I . Review of the techniques to determine receptor mechanisms control­
ling aqueous production
The interesting phenomenon that beta-blockers lower intra-ocular 
pressure by reducing aqueous production has stimulated research workers 
to examine the ciliary processes to determine whether these agents exert 
their effects through beta-adrenoceptors located in the epithelium of 
the ciliary processes. Three major pathways have been investigated to 
determine whether beta-adrenoceptors exist in the ciliary processes; 1 ) 
pharmacological techniques, 2 ) receptor adenylate cyclase interactions, 
3) radio-ligand studies.
A) Pharmacological techniques
Prior to the development of direct ligand binding studies, 
receptors were defined indirectly by observation and quantitation of 
certain physiological effects occurring subsequent to hormone or drug 
receptor interactions. Such studies have provided a great deal of 
information and have served to define the main patterns of drug 
specificity which, in turn, define most receptors. Therefore, on the 
basis of a large body of experimental data, beta-adrenoceptors have been 
defined as cellular structures which bind agonist catecholamines with a 
certain order of potency, namely:
Isoprenaline > adrenaline > noradrenaline (Ahlquist, 1948). Similarly 
antagonists have definable potency series with propranolol being amongst 
the most potent beta blockers.
Similar techniques have been used on the eye to try to determine 
the receptors controlling aqueous production and intraocular pressure 
(Nagasubramanian, 1982; Bonomi et al., 1981; Coakes et al., 1978;
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Townsend et al., 1980; Innemee et al., 1982; Sears, 1986). These 
indirect tests (which include the use of fluophotometry) have been 
extrapolated by various authors to implicate adrenergic receptors (and 
in particular beta-adrenoceptors) as being important in aqueous humour 
production. It is obvious, however, that these pharmacological tests do 
not allow for exact identification or anatomical location of the 
receptor sites controlling aqueous humour production. For example (-) 
timolol maleate, a non-specific beta blocker, may decrease aqueous 
humour in-flow but one cannot say with certainty that this effect on 
aqueous production is due to specific beta blockade of the ciliary 
process epithelial receptor sites as has been claimed by some authors 
(Aim et al., 1981). The effect on aqueous production could be due to a
vascular effect on the choroid or by some other as yet unidentified 
mechanism (Langham et al., 1979; Smith, 1987; Phillips, 1987).
Extrapolation of these indirect pharmacological tests has resulted 
in markedly differing opinions in the literature with regard to which 
receptors in which structures control aqueous humour production and 
intraocular pressure (Langham et al., 1979; Nagasubramanian, 1982; 
Coakes et al., 1978; Berrospi et al., 1983; Chiou, 1982; Sears, 1986; 
Phillips, 1987).
It is clear that if a technique was developed to detect beta- 
adrenoceptor in the ciliary processes of human or pigmented animal eyes, 
it would be of great help in resolving this controversy. The 
development of a direct radioligand binding technique to study ciliary 
process beta-adrenoceptors was therefore a major aim of this research 
project. Details of methodology and results are reported in the
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appropriate sections of this thesis.
B) Beta-adrenoceptor adenylate ^ cyclase interactions
As previously indicated Sutherland and Robison were the first to 
report that the stimulatory effect of catecholamines on adenylate
cyclase was initiated by beta-adrenoceptors (Sutherland et al., 1966).
Waitzman and Woods were the first authors to report that beta agonists 
activate adenylate cyclase in the ciliary processes of rabbit eyes 
(Waitzman et al., 1971). Neufeld has reported changes in aqueous humour 
cyclic AMP after adrenaline stimulation and sympathectomy (Neufeld et
al., 1973).
Recent in vitro work by Nathanson, Cepelik and Elena has revealed 
that animal and human ciliary process epithelium responds to beta 2
stimulants by producing cyclic AMP. This indirectly suggests that beta 
2 receptors exist in the ciliary processes (Cepelik et al., 1981; Elena
et al., 1981; Nathanson, 1980). This is an important observation in 
relation to the anatomical situation and the subtype of beta receptor 
controlling aqueous humour production.
Despite the advantages of studying beta-adrenoceptors coupled to
adenylate cyclase, such experiments are still considered indirect 
(Lefkowitz, 1976). The characteristics of the receptors being inferred 
from observed changes in enzyme activity.
C) Radioligand Studies
Until recently there were no methods to directly investigate 
adrenergic receptors. In 1974 beta adrenergic radioligand techniques 
were first described (Levitzki et al., 1974; Lefkowitz et al., 1974;
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Ai^rbach et al., 1974). As previously indicated these techniques allow 
the direct detection, characterization (sub-types) and concentration 
(i.e. receptor numbers) of beta-adrenoceptors in a tissue sample 
(Lefkowitz, 1976; Motulusky et al., 1982). Radioligand techniques have 
been applied to various tissues of the body including lymphocytes, 
platelets, placenta, lung, brain and other tissues. This work has been 
reviewed by Motulsky et al and Stiles et al (Motulusky et al., 1982; 
Stiles et al., 1984).
Very little work has been performed on the eye using radioligand 
binding studies. Most attempts to detect beta-adrenergic receptors 
using ligand binding techniques have been performed by Neufeld et al., 
(Neufeld et al., 1977; Neufeld et al., 1978). This work was performed 
on iris ciliary body homogenates from albino rabbit eyes. Albino 
rabbits were used as melanin present in non-albino animals binds ligand 
and distorts the results (see later). Major deficiencies in these 
studies are described later (see discussion). In 1980 Bromberg et al., 
described a novel radioligand technique to try to identify beta- 
adrenoceptors specifically in the ciliary processes of albino rabbit 
eyes (Bromberg et al. , 1980). This technique has never been verified
(see developments section). The successful development of a repeatable 
radioligand technique, applicable to small amounts of pigmented ocular 
tissue forms a large portion of this study (Trope et al., 1982).
59
VII. Review of Animal Models to Study Aqueous Humour Production and
Glaucoma
A) Measurement of Aqueous Humour Production
In 1981 Vareilles and Lotti (Vareilles and Lotti, 1981) described a 
technique to study aqueous humour production in rabbit eyes. This test 
was based on studies performed by Auricchio and Diotallevi in which
I.O.P. recovery rate curves were studied after eye ball compression 
(Auricchio and Diotallevi, 1965). The technique involves the use of 
hypertonic saline as an osmotic agent to temporarily lower I.O.P. 
Briefly, this technique involves initially measuring rabbit intra-ocular 
pressure. Drug under test is then placed onto one eye of a rabbit and 
the intra-ocular pressure remeasured. Hypertonic saline is then 
injected intravenously into the rabbit via a marginal ear vein at a 
rate of 1 ml/min over 10 minutes. At the end of the infusion I.O.P. 
rapidly drops and slowly returns to normal. Intra-ocular pressure is 
then measured at various time intervals throughout the experiment. If a 
test drug inhibits aqueous humour production, intra-ocular pressure
recovery will be delayed in that eye compared with both the untreated
eye and a control group of eyes. This technique has been used by a
number of investigators to study the effects of a variety of drugs on
aqueous humour production (Vareilles and Lotti, 1981 Chiou, 1982 
Chang et al, 1985 Conway et al, 1987). It allows one to determine 
aqueous humour production by measuring the slope of the intra-ocular 
pressure recovery line. The intra-ocular pressure recovery rate is
o
expressed in millimetres of mercury per minute. This technique was 
used to determine the effects of beta - 2 specific antagonists on aqueous
production.
B) Animal Glaucoma Models
Many workers have tried to induce glaucoma in rabbits and other 
animal eyes. Techniques that have been used to block outflow channels 
include injection of air, pigment granules, methylcellulose, red blood 
cells, ghost cells, cotton and mineral oil into the anterior chamber 
(Lessel and Kuwabara, 1969; Bartels, 1984; Shields, 1982). Ligation of 
vortex veins, diathermy and cautery of subconjunctional tissues at the 
limbus have also been tried (Gelatt, 1975). Other techniques to produce 
raised I.O.P. include; blunt trauma, water loading, encircling rubber 
bands, I.V. 5% glucose, and aqueous paracentesis with iris stimulation 
(Gelatt, 1977) (Bonomi et al, 1979). None of these techniques are 
reliable models of glaucoma with transient elevations of intra-ocular 
pressure being the usual response (Gelatt, 1977; Rowland and Potter, 
1980; Bartels, 1984). Alpha-chymotrypsin injection into the anterior 
chamber however can produce long-term elevations in rabbit intra-ocular 
pressure due to zonular fragments obstructing the outflow channels. 
This elevation in pressure however is associated with severe intra­
ocular inflamation, lens dislocation and vitreous disturbances with loss 
of the eye as a consequence on occasion (Sears, 1974) (Gelatt, 1977). 
Subconjunctional injections of 4 mg Betamethasone 3 times per week is 
claimed to induce ocular hypertension in rabbit eyes after 3-5 weeks. 
This technique however precludes the use of the second eye as a control 
and produces undesirable systemic effects (Bonomi et al, 1979).
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Experimental glaucoma has been induced in rabbits and rhesus 
monkeys by repeated circumferential argon laser photo-coagulation of the 
trabecular meshwork (Gaasterland and Kupfer, 1974) (March, Gherezghiher, 
and Coss et al., 1984). Due to the difficulties involved in visualizing 
the rabbit angle gonioscopically plus the expense and other difficulties 
of using monkeys, these animal models are not commonly used.
Congenital glaucoma occurs in rabbits (Fox et al., 1970) (Kolker et 
al., 1963) (Gellat, 1977) dogs and in chickens exposed to continuous
light (Kinnear, Lauber and Boyd, 1974). The rabbit glaucoma is due to 
an outflow obstruction and is characterized by large corneal diameter, 
cloudy cornea and raised intra-ocular pressure (Gelatt, 1977).
Buphthalmic rabbits have been reported as being good animal models 
for human glaucoma as they respond in a similar fashion to topical 
antiglaucoma drugs (Vareilles, Conquet, and Lotti, 1985). Breeding and 
maintenance of these rabbits however can be difficult (See Discussion).
In this study buphthalmic rabbits were used to investigate the 
effects of beta2 specific drugs on intra-ocular pressure.
VIII. AIMS OF THIS THESIS
1. To develop a radioligand technique to determine whether beta- 
adrenoceptors exist in the ciliary processes of pigmented eyes.
2. To determine the sub-type of receptors present in the ciliary 
processes.
3. To apply the results of the ligand binding study to the in- 
vivo situation:
a) To determine whether the appropriate beta-specific antagonists 
inhibit rabbit aqueous humour production.
b) To determine whether the appropriate beta-specific antagonists 
lower I.O.P. in rabbits with glaucoma.
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MATERIALS AND METHODS
This section deals with the methods used to detect and characterise 
beta adrenergic receptors in the ciliary processes (Trope and Clark, 
1982). It also contains details of techniques used to study intraocular 
pressure recovery rate (aqueous humour index) in rabbits and the 
measurement of intraocular pressure in rabbits with congenital glaucoma. 
I) In vitro study of beta receptors.
A) Dissection technique to isolate ciliary processes.
Eight eyes from freshly slaughtered sheep were obtained from an 
abattoir and immediately enucleated and placed on ice. The ciliary 
processes were dissected free from the rest of the eye as follows:
1) A posterior sclerotomy was made in the region of the equator 
to decompress the eye. A small amount of vitreous humour was allowed to 
prolapse from this incision.
2) An incision + 6 mm from and parallel to the limbus was made 
down to the choroid and extended 360 ° using scissors (Figure 7). Once 
complete the scissors were introduced into the anterior chamber from the 
suprachoroidal space through the scleral spur (Figure 8 ). This 
procedure enabled the cornea plus a rim of sclera to be peeled off the 
scleral spur (Figure 9). The iris was then dissected off the underlying 
iris/ciliary body diaphragm to reveal the ciliary processes (Figure 10). 
To free the ciliary processes the ciliary body was radially incised and 
then dissected free from the ciliary processes as indicated in Figure
11. The ciliary processes were then dissected off the lens and 
underlying vitreous using an operating microscope and microsurgical 
instruments (Figure 12). Within one hour of death the ciliary processes
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were freed and placed into cold saline and transported to the 
laboratory.
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Figure 7: Initial dissection procedure. Note posterior sclerotomy 
and 6 mm rim of sclera dissected off underlying choroid.
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Figure 8: Scissors introduced into anterior chamber through the 
scleral spur.
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Figure 9: Sclera and cornea peeled off scleral spur to reveal iris
and ciliary body.
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Figure 10: Iris dissected off ciliary body to reveal ciliary
processes.
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Figure 11: Ciliary body dissected from ciliary processes.
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Figure 12: Ciliary processes dissected off the lens and anterior
vitreous face using microsurgical techniques.
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B) Membrane Preparation
a) The ciliary processes from 8 eyes were pooled in a cellulose 
nitrate tube containing 3 ml of a buffer solution (pH 7.5) consisting of 
50 mmol/1 Tris and 1 mmol/1-ascorbic acid (buffer A) at 4°C.
b) The tissue was homogenized with an Ultraturrax (75 % full 
speed, 5 sec, at 4°C).
c) This homogenate was further homogenized in a ground glass 
homogenizer using 5 strokes.
d) The homogenate was allowed to stand for one minute in a ice 
bucket and then centrifuged at 3000 g for 20 minutes at 4°C.
e) The pellet was then resuspended in 3 mis of cold buffer A and 
further re-homogenzied with the Ultraturrax (25% full speed, 2 x 5  
seconds at 4°C).
f) The Ultraturrax was then washed with 1 ml of cold buffer A. 
This solution was saved and added to the homogenate.
g) The homogenate was then loaded onto a discontinous sucrose 
gradient consisting of 2 1/2 mis of 50% sucrose and 7 ml of 5% sucrose 
in buffer A plus 0.1% calf serum at 4°C. The cellulose nitrate tube was 
topped up with buffer A and placed in a balanced Beckman SW27 rotor and 
centrifuged at 131,000 g (22,000 rpm) 18 hours at 4°C. This process 
removed all melanin to the bottom of the tube (Figure 13) .
h) Membrane fragments were then removed from the interface 
(Figure 13) and placed in cold buffer A in a cellulose nitrate tube. 
The tube was then sealed and re-centrifuged at 3 0o,000 g for 3/4 of an 
hour at 4°C in a balanced beckman type 65 rotor head.
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i) This process produced a depigmented pellet (Figure 14). Table 
3 summarizes the membrane preparation technique.
j) The pellet was then re-suspended in the appropriate amount of 
assay buffer (pH 7.6) containing 20 mmol/l-Hepes, Earles balanced salt 
solution and 0.3 mmol/1-catechol at 4°C. Once in solution the membrane 
particles were transfered to a cold ground glass homogenizor where they 
underwent further homogenization (5 strokes) with a glass hand 
homogenizer.
Homogenization and Centrifugation Technique
Iris - Ciliary Body HomogenizedX
JJ, 0 0 0  g for 2 0  mins
Suspension Pellet Resuspended
I  !
Discarded 131,000 g x 18 hours on Sucrose gradient
Melanin Pellet 
Discarded Membrane Fragments at Interface
V
300,000 g x 3/4 hour
V
Pellet Resuspended and Homogenized
l
Assay
Table 3: Membrane preparation technique for ciliary processes.
g = gravitational force.
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Figure 13: Melanin displaced to bottom of the tube after
ultracentrifugation at 300,000 g for 18 hours on a
sucrose gradient. Note interface of cell membrane
fragments between 5%: 50% sucrose gradient (see bracket).
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Figure 14: Pellet obtained from sucrose gradient interface. Pellet
obtained by ultracentrifugation at 300,000 g for 3/4 of 
an hour at 4°C.
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C) Ligand Binding Techniques
1) Saturation experiments.
Saturation assays were prepared on ice and done in polypropylene 
tubes in a final volume of 250 ul.
a) For total binding:
1 ) 1 0 0  ul of assay buffer was placed in duplicate test tubes.
2) 100 ul of homogenized cell membrane preparation (5-20 ug
protein) was then added to each tube.
l o t ;
3) 50 ul of [ I]-HYP in concentrations ranging from 25 - 500 pM 
was next added to the appropriate tubes.
b) To determine non-specific binding:
1) 50 ul of assay buffer was initially placed into duplicate 
tubes.
2) 50 ul of 1 uM (-)propranolol was then added to the tubes.
-loc
3) 50 ul of the appropriate concentration of [ I]-HYP was then 
added to the mixture.
4) finally a 100 ul of cell membrane suspension was placed in
appropriate tubes.
Totals and non-specific binding were all estimated in duplicate at 
125all [ I]-HYP concentrations. See subsection 4 for incubation and 
filtration proc edures.
Radioligand dilutions from 25 - 500 pM were prepared from stock in 
assay buffer (without catechol) using a dilution program developed by 
Clark for use on the Apple computer and Wang microprocessor (Clark et 
al., 1983).
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All drugs were freshly prepared in assay buffer (without catechol). 
Table 4 reviews details of the amounts and concentrations of cold 
drug, buffer, radioactive ligand and membrane used in these saturation 
experiments.
2) Competition Curves/Stereospecificity and Characterization 
Experiments
All of these experiments were prepared on ice and done in 
polypropylene tubes in a final volume of 250 ul. Table 5 reviews 
volumes and concentrations of agents used. For total binding:
a) 1 0 0  ul of assay buffer was placed in the tubes.
b) 50 ul of radioligand was then added to the tubes.
c) 100 ul of membrane suspension (5-20 ug protein) was then added 
to the tubes.
In the competition (test) tubes, the following was inserted:
a) 50 ul of buffer was placed in each of the tubes.
b) 50 ul of the appropriate concentration of cold ligand was then 
added to the tubes.
c) 50 ul of a fixed concentration of radioligand was then added to 
the tubes.
d) 100 ul of membrane suspension (5-20 ug protein) was finally
125placed in the tubes. 450 pM of [ I]-HYP was the concentration used in 
these experiments. Specific activity was 1,850 Ci/mmol. See section
4 for washing and filtration procedures.
Each experiment was performed from two-four times, using duplicate 
preparations and on occasion triplicate preparations.
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Drugs used in these experiments included (-) and (+) propranolol, 
practolol, betaxolol hydrochloride, salbutamol, IPS 339, LI - 32-468, 
ICI 118551 and (+) timolol maleate.
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1) Buffer
2 ) 1  uM (-)Propranolol
3 ) [1 2 5 I]-HYP*
4) Membrane
*[125I]-HYP : 25 - 500 pM
Total binding
1 0 0  ul 
Nil 
50 ul 
1 0 0  ul
Non-Specific 
binding 
50 ul 
50 ul 
50 ul 
1 0 0  ul
Table 4: Volumes and concentrations of agents used in saturation
and kinetic experiments.
Total Test
1) Buffer 100 ul 50 ul
2) Drug (10"n M - 10"3 M) Nil 50 ul
3) [1 2 5 I]-HYP* 50 ul 50 ul
4) Membrane preparations 100 ul 100 ul
*[1 2 5 I]-HYP = 450 pM
Table 5: Volumes and concentrations of agents used in competition
stereospecificity and characterization experiments.
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3) Kinetic Experiments
A) Time Course of Binding (Association)
For these experiments a final volume of 250 ul was used. 
Radioligand concentration was 450 pM. Duplicate preparations of total 
and non-specific binding tubes were prepared on ice in volumes as 
indicated in table 4 except that membrane preparations were added to the 
tubes at 5 second time intervals beginning with the last assay tube 
(i.e. the 90 minute tube first). After membrane preparations had been 
added to all tubes, the assay mixtures were then incubated for specific 
time intervals: 1 minute, 2.5, 5, 10, 15, 20, 30, 40 , 60 and 90
minutes. At the end of each of these periods assay tubes were removed 
from incubation and the reaction stopped with Tris saline, filtered and 
washed as indicated below (See section 4).
B) Reversal of Binding (Dissociation)
For this experiment duplicate assays consisting of total and non-
I O  C
specific binding tubes were prepared using 450 pM of [ I ] - H Y P  (See 
Table 4). Total volume in each tube was 50 ul, (i.e. Buffer, colddrug, 
radioligand and membranes were all made up in one fifth volume) . All 
tubes were incubated for 40 minutes at 35°C.
At the end of 40 minutes all samples were transfered to ice and 
diluted with 5 mis of cold buffers (100 x dilution) . The reaction was 
then stopped, filtered and washed at times 0, 3, 6 , 10, 20, 30, 60 and
1 2 0  minute intervals using procedures as detailed below.
Association and dissociation experiments were performed at least 
three times.
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4) Incubation Washing and Filtration Procedures
For all the above experiments the assay mixtures were prepared on 
ice and incubation was commenced by transfer of the agitated tubes to a 
36°C water bath at 30 sec intervals. When transfer was complete, the 
bath was covered and the samples incubated in the dark (to minimize 
photolysis of the [^**I]-HYP) for 40 minutes.
Each reaction was stopped by adding 2.5 ml of buffer B (pH 7.5) 
consisting of 50 mmol/1 Tris, 0.9% sodium chloride and 0.1 mmol/1 + 
propranolol. Each sample was then allowed to stand for 45 seconds in 
this buffer before filtering through Whatman GFC fibreglass filter 
papers which had been pre-soaked for 90 minutes in buffer B. 
Filtration occurred by applying a vacuum of 4 pounds per square inch to 
a series of millipore filtration bowls. The membranes in each chamber 
were washed using a zipette with 3 x 8 ml of buffer C (pH 7.5) 
consisting of 50 mmol/1 Tris and 0.9% sodium chloride buffer. Filtering 
and washing was completed within 12 seconds. Table 6 summarizes the 
constituents of the various buffers and solutions used in all of the 
above experiments.
Radio-activity (c.p.m.) on the filters was determined using a 
Packard Auto Gamma Scintillation Spectrometer. For the saturation and 
kinetic experiments 50 ul of each standard was placed on a GFC filter 
paper in a test tube and radioactivity counted.
Protein levels were estimated for each experiment using a 
spectroscopic technique utilizing the commercially available Bio-Rad 
kit.
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Table 7:
Table 8:
Table 9:
This table documents chemicals and radioligands used in the 
experiments.
This table documents equipment used in this study.
This table details the cold drugs studied and the 
manufacturers names.
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Buffer A - pH 7.5
1. 50 mmol/1 Tris
2. 1 mmol/1 Ascorbic Acid
Assay Buffer - pH 7.6
1. 20 mmol/1 Hepes pH 7.6
2. 2 mis Earles Balanced Salt 
Solution (without sodium 
bicarbonate) in 18 mis ^ 0
3. 0.3 mmol/1 Catechol
Buffer B - pH 7.6
1. 50 mmol/1 Tris
2. 0.9 % sodium chloride
3. 0.1 mmol/1 (+)propranolol
Buffer C - pH 7.6
1. 50 mmol/1 Tris
2. 0.9% sodium chloride
Table 6 : Components of buffers
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1. Trizma base (2-Amino-2-hydroxymethyl-propane-1,3-dioz) (Tris)-Sigma 
Chemical Company Ltd., USA and England.
2. Ascorbic Acid - AnalaR-BDH Chemicals, Poole, England.
3. Earles balanced salt solution without Na HCOg - Gibco Bio-Cult Ltd. 
Paisley, Scotland.
4. Hyalase ovine powder - Fisons Loughborough, England.
5. Aseptic calf serum - Gibco Bio-Cult Ltd. Paisley, Scotland.
6 . Sodium Chloride-AnalaR-BDH Chemicals Ltd. Poole, England.
7. Hepes buffer Powder (4-(2-Hydroxyethyl)-1-Piperazinethanesulphonic 
Acid) - Flow Labs Ltd. Ayrshire, Scotland.
8 . Catechol (O-dihydroxybenzene)-BDH Chemicals Ltd. Poole, England.
9. Inderal (+ Propranolol Hydrochloride 1 mg/ml) for injection - ICI 
labs, England, U.K.
10. Bio-Rad Protein Assay kit Cat./No 500-0001.- Biorad Labs, Watford, 
England.
11. RADIOLIGANDS
A. [125i]-iodohydroxybenzylpindolol: Specific radio-activity
2200 Ci/mmol- New England Nuclear, Dreieich, West Germany.
Table 7: Chemicals and Radiochemicals with manufacturers names.
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I Vacuum pump - general electric No 5KH33EN251.
II Water bath - Grant x Co. Cambridge, U.K.
III Millipore filtration bowls - No xx270 2550. Millipore (U.K.) Ltd. 
Middlesex, England.
IV Glass microfibre filter papers GF/C 2.5 mm - Whatman Lab Sales, 
Maid Stone, England.
V Polyproprolene tubes (12 x 75 mm) Cat. No 55 526 - (Canlab)
Sarstedt Ltd. Leicester, England.
VI Beckman centrifuge cellulose nitrate tubes 5/8" x 3" No 
302235/344085.
VII Ultraturrax type TP 18110 - Jankel and Kunkel lKA-Products, 
Belmont, Surrey.
VIII Beckman ultracentrifuge Type L5-65: Beckman Inst. Inc. California,
U.S.A.
Rotors: Type 65 No E4 165
Type SW 24 for CDFG
IX Zipette 10 ml - Jencon Scientific Ltd. U.K.
X Macro Oxford 10 ml pipette.
XI Finnpipettes 50 - 250 ul, 0-50 ul, 250 ul - 1,000 ml.
XII Packard auto gamma scintillation spectrometer.
Table 8: Instruments, Consumables and Disposables used in these
experiments.
I Salbutamol. Allen & Handbury Ltd. Middlesex, England.
II (-) and (+) timolol maleate - Merk Frosst (M.S.D.), Quebec, Canada
and Hoddesdon, England.
III (-), (+) and (+) propranolol - Imperial Chemical Industries 
(I.C.I.) Pharmaceuticals Division, Cheshire, England.
IV LI 32468 - Sandoz, Basel, Switzerland.
V IPS 339 - Dr. LeClerk, University Louis Pasteur, Strasbourg,
France.
VI ICI 118551 - ICI - Cheshire, England.
VII Practolol - ICI - Cheshire, England.
VIII Atenolol - ICI - Cheshire, England.
IX (-) Metoprolol Hydrochloride- Ciba-Geigy Pharmaceuticals Division, 
Horsham West Sussex, U.K.
X Betaxolol Hydrochloride - Alcon Labs, Fortworth, Texas, U.S.A.
Table 9: Drugs with manufacturers names.
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II. Intraocular Pressure Recovery Method (Aqueous Formation Index).
Six pigmented rabbits were used to investigate each drug. A one 
week wash out period was used between experiments. All rabbits were 
accommodated to handling and to the restraint boxes in the laboratory 
environment prior to the study.
Intraocular pressure readings were obtained using a Digilab pneuma- 
tonometer which had been calibrated for rabbit eyes (see developments 
section). (Moses and Grodezki, 1979). Pressure readings were taken 
three times and the mean used as final IOP. Topical anaesthesia was 
placed in the eye of each animal before I.O.P. readings were measured 
(1/2% Proparacaine Hydrochloride).
Intraocular pressure was measured before instillation of drug or 
buffer. 1 0 0  ul of drug was then instilled into each rabbit lower 
conjunctival fornix using a micropipette. 1 0 0  ul of phosphate buffer 
solution was placed into the lower fornix of the animals second eye. 
Drug and buffer administration were performed randomly in a masked 
fashion. I.O.P. was then re-measured 50 minutes later. A 23.4% 
solution of sodium chloride was then infused intravenously into each 
rabbit via a marginal ear vein at a rate of 1 ml/minute over a period of 
10 minutes using a Sage pump. At the end of this infusion period 
intraocular pressures were measured at the following time intervals 0 , 
5 min, 10 min, 15 min, 20 min, 40 min, 50 min, 60 min, 70 min, 80 min, 
120 min, 130 min, and 140 min or until intraocular pressure recovered to 
preinfusion values in one or both the eyes.
A control experiment was initially performed as described above but 
buffer alone was placed in one eye. The purpose of having control eyes
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was to determine whether systemic absorption of drug influenced I.O.P. 
recovery rate in the second eye (consensual effect) (See Discussion). 
The same six rabbits were used throughout the study.
Compounds studied included a non-specific beta blocker (-) timolol 
maleate (Timoptic (Merk Frosst)), a beta-1 specific blocker betaxolol 
hydrochloride (Betoptic (Alcon)) and three beta-2 specific blockers 
namely IPS 339 (Dr. G. LeClerk, Strasborg) LI32-468 (Sandoz), and ICI 
118551 (I.C.I.). All compounds used were either commercially prepared 
(1/2 % Timoptic and 1/2% Betoptic) or were freshly prepared as a 1%
solution in phosphate buffer pH 7.4 (IPS 339, LI 32-468, ICI 118551).
Table 10, documents instruments and materials used in sections II 
and III of this study.
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1. Digilab pneuma-tometer: Digilab Model 30D pneuma-tonometer,
Cambridge, Mass., U.S.A.
2. Sodium chloride for intravenous injection: Lymphomes Canada Inc., 
Mississauga, Ontario.
3. Phosphate buffer pH 7.4: Fisher Scientific New Jersey, U.S.A.
4. Sage syringe pump model 351.
Table 10: Instruments and materials used to measure intraocular
pressure recovery rate and I.O.P. in normal and buphthalmic
rabbit eyes.
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III. Method to determine the effects of beta-adrenergic antagonists on
intraocular pressure in buphthalmic rabbits
For this series of experiments 5 buphthalmic New Zealand albino
rabbits supplied by Maple Lane Farms, Toronto, were studied.
All rabbits were allowed a minimum of three days to become 
accustomed to animal handling.
Topical anesthesia was placed in the eye of each animal before 
intraocular pressure readings were measured (1 / 2 % proparacarhe 
hydrochloride).
Each rabbit was initially subjected to a diurnal pressure curve 
using a digilab pneuma-tonometer over a 12 hour period from 7 am to 7 
pm. These pressure readings were used as the experimental control. A 
mean of three readings was taken to be the actual pressure. Diurnal 
curves were performed within 1  week of each experiment and were 
repeated for each drug.
Intraocular pressure was initially measured in both eyes of each 
animal + 10 minutes before drug administration. At 7 a.m. (t = 0 min) 
50 ul of a 1/2 - 1% dose of test drug or phosphate buffer was randomly
administered in a masked fashion to ane eye of each rabbit with
congenital glaucoma. The second eye was not treated but its intraocular 
pressure was measured over the test period. Intraocular pressures were 
measured every 15 minutes for the first hour, every 30 minutes for the 
second hour, and then hourly for the duration of the experiment ( 1 2  
hours). After the first hour of experimentation the animals were
returned to their cages. They were subsequently removed for each 
pressure check and then returned. The experiment was repeated a week
later alternating test drug and buffer.
A wash out period of at least a week was allowed before each rabbit 
underwent further testing. Compounds studied in this section of the 
study included IPS 339, ICI 118,551, LI 32-468, 0.5% (-) timolol maleate 
and 0.5% betaxolol Hydrochloride.
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IV. Analysis of Data
A. Saturation binding and competition curves were drawn and analyzed 
using micro-processor assisted curve fitting programs, as published by 
Clark et al (Clark et al., 1983; Clark et al., 1984). Kinetics of 
binding data was analysed and drawn using a computer program developed 
by Steinberg et al (Steinberg et al., 1985)
B. The least squares method was used to determine intraocular pressure 
recovery rate (aqueous humour index) over time for each rabbit. 
Analysis of variance of the change in I.O.P. over time was performed. 
Comparisons were tested using the F test.
C. Analysis of variance was used to determine Drug effects in 
buphthalmic Rabbits. The sources of variation considered were:
1. Variation among different rabbits.
2. Differences between the times of measurement.
3. Differences among the treated eye, untreated opposite eye and 
the same control eye.
4. Random variation.
The test statistic used was the F statistic. The amount of random 
variation was used to estimate the standard error of the mean intra­
ocular pressure for each time and treatment when required.
Three treatment effects were studied:
1) Differences among the three treatments i.e. the treated eye, 
the corresponding control eye and the untreated opposite eye.
2) Changes occuring over time e.g. 1 and 2 hours after treatment.
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3) Interaction between treatment and time i.e. was the difference 
(if any) between treatments the same at 1  hour after drug instillation 
as at 2 hours.
When examining short-term effects, the measurements at time 0, 
before any treatment was given, was used as a co-variable; thus 
controlling for the starting values of intra-ocular pressure in the 
analysis for all rabbits eyes. The mean I.O.P. readings at 2 hours was 
used to express the mean results in percentage terms.
For sections B and C statistics were performed at the Universityxof 
Toronto, Canada by Dr. M. Chipman, Ph.D., Director, Clinical Research 
Support Unit.
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DEVELOPMENTS
I. Development of Radioligand Technique
The development of radioligand techniques performed on the ciliary 
processes evolved from a series of experiments performed on sheep iris
ciliary body diaphragm. These initial experiments were in many cases
not verified in view of the fact that they were performed during an 
early stage of this project.
A. Dissection of Iris ciliary body diaphragm and ciliary processes.
The technique used to dissect ciliary processes as outlined in the 
materials and methods section was developed from iris ciliary body
diaphragm dissections. After the first few attempted dissections of
ciliary body it soon became apparant that a posterior sclerotomy was 
required to initially decompress the eye. This sclerotomy allowed
anterior segment structures to settle back. A second circumferential
incision down to the suprachoroidal space enabled removal of the cornea 
from the scleral spur without distorting anterior segment anatomy. Iris 
ciliary body was dissected free from choroid using an operating 
microscope. Finally, iris-ciliary body diaphragm was dissected off the 
anterior vitreous face and lens.
This technique was modified for ciliary process experiments by 
freeing the ciliary body from its attachments to the chloroid and then 
removing the iris (Figure 15). This allowed the ciliary body to be 
gently elevated off its vitreous attachments and under tension expose 
the ciliary processes attached to the lens. The ciliary processes were
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dissected from the ciliary body and finally dissected off the lens and 
placed in cold buffer A. Later, as surgical skills improved, a time 
saving surgical procedure was performed which involved removing iris 
from the ciliary body to allow direct visualization of the ciliary 
processes. Ciliary processes were then directly freed from attachement 
to ciliary body and then dissected off the lens with De Weckers scissors 
using an operating microscope as indicated in the methods and materials 
section. All dissections were performed on ice and took twenty to 
thirty minutes per eye.
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Figure 15: Ciliary body dissected from its attachment to the choroid
before ciliary processes dissected off the lens. Later 
experiments ciliary body was not dissected from choroid.
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B. Membrane Preparation and Binding Technique Developments.
Initially an attempt was made to duplicate the membrane preparation 
and binding technique described by Bromberg et al (Bromberg et al., 
1980). It soon became apparent however that this technique was 
impossible to repeat using eyes containing pigment, as pigment bound 
virtually all the radioligand making it impossible to determine specific 
binding. Furthermore, this technique was extremely difficult to perform 
and unconventional in that it involved puncturing discontinuous sucrose 
gradients and collecting various fractions including the membrane 
interface without adequate techniques to separate bound from free 
ligand.
Bromberg did however report that maximum binding seemed to occur at 
the 5:50% interfacing of a discontinuous sucrose gradient after a 1 hour 
spin at 190,000 g. It was therefore decided to continue to use a 
sucrose gradient technique but to modify the gradient concentration and 
spin time so as to both collect membrane fragments and get rid of the 
melanin to the bottom of the tube. Various gradients and spin times 
were tried. As indicated on table 11, a spin time of 18 hours at
131,000 g on both a 5:75 %, and 5:50 % sucrose gradient in Buffer A 
produced a melanin free membrane interface with a melanin pellet at the 
bottom of the tube.
The next stage of development was to ensure that the interface was 
indeed 1) made up of membrane fragments and 2) melanin free. The tissue 
derived from the interface was pelleted by spinning at 131,000 g for 3 
hours (later, this was modified to 300,000 g for 3/4 hour for ciliary 
processes experiments (table 3) . The pellet was fixed in tissue
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fih^tive and studied by transmission electron microscopy in the 
Department of Ophthalmic Pathology and verified by members of the 
Department of Dermatology, University of Glasgow. Figure 16 is a 
electron micrograph showing melanin free ciliary epithelial membrane 
fragments obtained from the 5:75 % sucrose density gradient interface. 
Similar melanin free membrane fragments were derived from ciliary 
process tissue preparations at the 5:50 % interface.
Membrane Preparation Technique 
Iris - Ciliary Body Homogenized
3 , 0 0 0  g for 2 0  mins
SupernatantI
Discarded
Melanin Pellet
Discarded
Pellet Resuspended 
1
131,000 g x 18 hours on Sucrose gradient
Membrane Fragments
131.000 g x 3 hours
^ *
300.000 g x 3/4 hour
Pellet Resuspended 
*
Assay
Table 11: Homogenization and spin technique to prepare membrane 
fragments from iris/ciliary body diaphragm and ciliary 
processes.
g = gravitational force.
* = ciliary processes.
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Figure 16: Transmission electron micrograph showing melanin-free
membrane fragments isolated from the 5%:75% sucrose 
density gradient interface. (Magnification x 8000).
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At this stage a simple experiment was performed which confirmed
that Brombergs technique of adding radioligand to homogenised ocular
tissue was inappropriate for pigmented eyes (Bromberg et al., 1980). 50 
125pM of [ I]-HYP was added to homogenised pigmented iris ciliary body 
diaphragm and incubated for 30 minutes at 36°C. The suspension was 
layered on a 5:75% sucrose gradient and spun at 131,000 g for 18 hours. 
At the end of the spin the melanin pellet and membrane fraction were 
separated and their radioactivity measured. Ocular melanin bound 98.9% 
of the counts. The membrane fraction bound 0.58%.
The next stage of the study was spent developing the binding 
technique.
All buffers and general techniques used to study and characterize
beta receptors were derived from standard radioligand binding techniques
as described by Yamamura et al. , Nahorski et al. , and Titinchi et al.,
(Yamamura, 1975; Nahorski, 1978; Titinchi, 1983).
As indicated in the material and methods section, all preliminary
and final experiments were performed in a final volume of 250 ul
(Nahorski, 1978). Routine filtration and washing techniques were
utilized. One extra procedure however was performed. This involved the
use of a "stopping" solution consisting of 50 mmol/1 tris (pH 7.5) 0.9
% sodium chloride and 0.1 mmol/1 (+) propranolol at 36°C (Buffer B).
This 45 second stopping procedure was performed before filtration and
washing. It was performed for a number of reasons. Firstly, it was
felt that dilution of the 250 ul sample with 2.5 ml of stopping solution
would minimize sample loss on transfer of the tube contents to the
125millipore filter bowl. Secondly, the [ I ] - H Y P  concentration falls by
100
a factor of 11 on the addition of 2.5 ml. Since the kinetics of binding
of non-specifically bound ligand are more rapid then those of
specifically bound ligand, it was felt that this stopping procedure
would increase the tendency for non-specifically bound ligand to leave
the membrane (Maguire, 1976). Thirdly, this process is assisted by the
use of propranolol at 0 . 1  mmol/ 1  which for similar reasons encourages
125non-specifically bound [ I ] - H Y P  to leave the membrane while not
significantly affecting specifically bound ligand.
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Since [ I]-HYP also binds avidly to GFC filters buffer B was used 
as an anti-adsorbant. Towards this end the filter papers were presoaked 
in this buffer for 90 minutes. After filtration and washing, all 
filters were air dried overnight at room temperature and radioactivity 
measured in an auto-gamma scintillation spectrometer as indicated in the 
methods and materials section.
Tables 12 and 13 indicate volumes and concentrations of agents used 
in the initial saturation and competition studies on membrane 
preparation derived from iris ciliary body diaphragm. As indicated on 
Table 13 initial concentration of radioligand was 150 pM.
The next section contains the preliminary binding results on 
ciliary body diaphragm and ciliary processes.
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Total Non-Specifc
Binding
Buffer 1 0 0  ul 50 ul
1 uM (-)propranolol Nil 50 ul
[1 2 5 I]-HYP* 50 ul 50 ul
Membrane Preparation 1 0 0  ul 1 0 0  ul
*[1 2 5 I]-HYP: 25-500 pM
Table 12: Volumes and concentrations of agents used in saturation
binding experiments on iris ciliary body diaphragm.
Total Non-Specific
Binding
Buffer 
Drug (10" 
[1 2 5 I]-HYP*
Membrane
- 10"3 M)
1 0 0  ul 
Nil 
50 ul 
1 0 0  ul
50 ul 
50 ul 
50 ul 
1 0 0  ul
*[125 I]-HYP = 150 pM
Table 13: Volumes and concentrations of agents used in
competition/stereospecificity/characterization 
experiments.
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C) Preliminary Binding Results on Iris Ciliary Body Diaphragm and
Ciliary Processes
Figure 17 illustrates a representative example of 1 of the 2 early 
saturation studies on iris ciliary body diaphragm. As indicated 
computer analysis of the data revealed Bmax of 72.9 fmol/mg protein. 
was 140 pM. Correlation coefficient was 94.9%.
A repeat study (graph not shown) revealed a Bmax of 122 fmol/mg 
protein with a of 120 pM. Correlation coefficient for the 6 points 
was 91.8%.
The mean Bmax for the 2 experiments was 97.45 fmol/mg protein. The 
mean was 130 pM.
As this saturation data looked encouraging, a competition curve
17 S
using (+) and (-) propranolol was performed using 150 pM [ I ] - H Y P .
Figure 18 indicates the results of the stereospecificity experiment 
using (+) and (-) propranolol.
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125i-h y p  s p e c i f i c  b o u n d
45 r
72.9
0.14
94.9%
Bmax:
K d:
Corr:
B/F
RECEPTOR NUMBER
0 1601 2 0
S T A N D A R D  (pM) 
f ig  17 Saturation study (1 ) o n  sheep iris ciliary 
b o d y  diaphragm. x
1 O tr
Figure 17: Specific binding of [ ]I-HYP to sheep iris ciliary body
diaphragm receptor sites. Insert, Scatchard plot of 
[1 2 5 I]-HYP binding.
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C.P.M .x 1,000
2 0 1
1 6 -
(+) Propranolol
12-
(-) Propranolol \
NSB
-100 9 8 7 -6 5 4
log [Propranolol] M
Figure 18: Stereospecificity competition curve performed on membrane
preparations from iris ciliary body diaphragm.
[T = Total binding, NSB = Non-specific binding.]
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[L]
values derived using the formula = IC^q /(1 +----- ) were:
k d
(-) propranolol:4.36 x 10 M
(+) propranolol:3.28 x 1 0 M.
This figure is typical of a stereospecific beta receptor (i.e. 
there is a difference in potency by a factor of 75).
Figure 19: This first "Reefit" computer generated competition
curve shows that the beta2 selective drug, salbutamol, displaced 
radioligand more potently than the beta-^ specific drug practolol, 
suggesting a preponderance of beta2 receptors in this tissue. Reefit 
computer analysis of the raw counts revealed a two site fit for each 
drug, indicating a mixed receptor subpopulation (i.e. beta-^ and beta2 ) 
in the iris ciliary body diaphragm.
Table 14: This table reviews the K^'s and receptor subtypes
derived from computer analysis of the curves drawn in Figure 19. As 
indicated beta-2 adrenoceptors made up between 75% - 91% of the beta- 
adrenoceptors in this tissue.
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1125 I-HYP
%  Specific Binding
lOO-i
80-
6 0 -
'▲ Salbutamol
4 0 - ■V Practolol
20-
9 8 - 7 6 5
LOG (Substance) mol/1.
Figure 19: Competition curve comparing the potencies of salbutamol
with practolol.
107
Compound
)>y
Constants
Receptor
Subtypes
Selectivity
Ratio
In %
Beta-1 Beta-2 Beta-l/Beta-2
Salbutamol 1.1 x 1 0 3 . 0  x 10"^ 25/75 37
(Beta-2 selective)
Practolol 3.2 x 10' 7 4.9 x 10 " 5 9/91 153
(Beta-1 selective)
Table 14: The tfFfiNlTy constants (Hi) and relative
concentrations of B-^  and B 2  receptors in iris ciliary 
body diaphragm derived from Reef it analysis of data.
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Once confident that binding could be performed on iris ciliary body 
diaphragm membrane preparations we then proceeded towards the main
objective of the binding study namely to study ciliary processes.
Initially a few competition curves were tried on the ciliary process
before an attempt was made to verify the results. These preliminary 
results are documented below.
Figure 20: This graph documents results of the first competition curve
attempted on ciliary process membrane fragments. (-) and (+)
propranolol were used as cold ligand.
[1 2 5 I]-HYP used was 420 pM.
Reefit analysis of the data revealed a one site fit: 
for (-) Propranolol «= 4.6 x 1 0 " %  
for (+) Propranolol = 3.8 x 1 0 " %
Figure 21: This computer drawn displacement curve was generated using
(-) metoprolol as cold ligand. Analysis of raw counts revealed a 1 site
fit with a of 2 . 1  x 1 0 "%.
Atenolol a B-^  blocker, nadolol (+) propranolol and (-) timolol
maleate all non-specific beta blockers (graphs not included) were also
studied during this early development stage of the study. K-_ for
atenolol was 2 . 2  x 1 0 "%. for nadolol was 2 . 2  x 1 0 ”% .  for (+)
- 9propranolol was 7.9 x 10 M. for (-) timolol maleate was 6.4 x
g
10 M. Reefit analysis revealed a 1 site fit for all data derived using 
these drugs.
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125i - h y p
% Specif ic Binding
x (-)  Propranolol 
•  (+) Propranolol
10CH
8 0 -
6 0 -
4 0 "
20-
-10 8  - 7  - 6
Log (Substance) m o l/I
Figure 20: The first competition curve performed comparing the
relative potencies of (-) and (+) propranolol to displace 
[125i j _h y p off ciliary process membrane fragments.
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Figure 21: Computer drawn competition curve using (-) metoprolol as
cold ligand. The 7 points are mean values of duplicate 
samples.
D) Results of Ligand Binding Studies on Ciliary Processes
Once satisfied that it was possible to perform radioligand binding 
on pigment free iris ciliary body and ciliary process membrane 
preparations, attention was specifically aimed at detecting and 
characterising beta receptors in the ciliary processes.
Most experiments were performed three times with the final results 
expressed as mean and standard error.
Figure 22:
This representative computer derived saturation curve and scatchard
analysis (insert) is characteristic of a receptor study. As indicated
125[ I ] - H Y P  bound to ciliary process membrane receptors in a saturable 
manner.
®max = 98.4 fmol/mg protein
Kd = 0.350 nM
Correlation coefficient = 98.8%
Two further saturation binding studies were performed (graphs not
shown). The results were:
^max = fmol/mg protein
Kd = 0.350 nM
Correlation 
Coefficient = 96.9%
II) Bmax = 8 5.6 fmoles/mg protein
Kd = 0.34 nM
Correlation 
Coefficient = 99.6%
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The mean (+ S.E.M.) results for the above three experiments were: 
= 98.0 (+ 7.30) fmol/mg protein
IllaX
Kd = 0.363 (+ 0.0185) nM
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125i-h y p  s p e c i f i c  b o u n d
(fmol/mg Protein)
I G 22 :
Bmax: 98.4 
Kd: 0.35
Corr: 98.8%
B/F
100
BOUND
370 555
S T A N D A R D  (pM)
Saturation curve a n d  ^
Scatchard analysis (insert) of 125I-HYP 
binding to ciliary process beta receptors.
Each point is the m e a n  of duplicate preparations.
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Figure 23:
This representative figure is a 1 site fit competition curve using 
(-) propranolol as cold ligand. This experiment was performed as part 
of a stereospecificity study using the same membrane preparation as 
figure 24. Each point is the mean of duplicate prepreparations. This 
figure indicates that (-) propranolol potently displaced radioligand 
from ciliary process beta receptors.
Q
Reefit analysis of the data revealed a of 1.44 x 10 M.
Two further competition curves (graphs not included) were performed 
as part of stereospecificity experiments using (-) propranolol as cold 
ligand.
The K^'s were: 1.16 x 10"8 M.
1.0175 x 10"8 M.
Both were 1 site fit competition curves.
The mean (+ S.E.M.) results for the three experiments using (-) 
propranolol = 1.20 (+ 0.12) x 10" 8 M.
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Figure 23: Representative 1 site fit competition curve using (-)
propranolol as cold ligand.
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Figure 24:
This representative 1 site fit competition curve was generated as 
part of a stereospecificity experiment using (+) propranolol as 
competing cold ligand. The same membrane preparation was used as in 
figure 23. This graph indicates fairly potent displacement of 
radioligand from ciliary process beta-receptors.
The for this study was 3.76 x 10"^ M.
Two other similar competition experiments using (+) propranolol 
were also performed (graphs not shown). A 1 site fit competition curve 
was generated in each case.
for the second (+) propranolol experiment was 2.77 x 10”^M. 
for the third (+) propranolol experiment was 3.67 x 10 "^M.
The m e a n  (+ S.E.M.) of the three e x p e r i m e n t s  u s i n g  (+) 
Propranolol as cold ligand = 3.4 (+ 0.3) x 10"^ M.
As previously indicated the mean of the three experiments using (-) 
propranolol as cold ligand = 1.20 x 10"® M. This + 30 fold difference 
between the mean values for (+) and (-) propranolol is consistant 
with the presence of stereospecific beta-adrenoceptors in ciliary 
process membrane fragments (See Discussion).
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Figure 24: Representative competition curve using (+) Propranolol.
Each point is the mean of duplicate samples.
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Figure 25:
This representative 1 site fit competition curve was generated 
using salbutamol as cold ligand. This study was performed on the same 
membrane preparation as figure 26 as part of a characterization 
experiment to determine ciliary process receptor subtypes.
The results of this experiment revealed a 1 site fit: 
for salbutamol = 1.96 x 10"^ M.
Two other characterization/competition experiments were performed 
using salbutamol. Reefit analysis revealed a 1 site fit graph in both 
cases. The result of the two other experiments were;
K t = 1.46 x 10' 5 M. 
and = 1.524 x 10"^ M.
Mean for the three salbutamol experiments = 1 . 9 9  (+ 0.50) x 
10'5M.
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Figure 25:
-6 -5  -4
Log [Salbutamol (M)]
-3
Representative 1 site fit competition curve generated 
with salbutamol as cold ligand. Each point is the mean 
of duplicate preparations.
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Figure 26:
This experiment was performed on the same membrane sample as
experiment 25 as part of a characterization experiment to determine
receptor sub-types. In this case practolol (beta-^ blocker) was used as
125competing cold ligand. This graph shows weak displacement of [ I ] - H Y P  
from ciliary process beta receptors.
The result derived from this 1 site fit competition curve =
1.10 x 10" 4  M.
Two further similar experiments were performed, 
for the second experiment = 0.82 x 10" 4  M.
for the third experiment = 1.013 x 10 " 4  M.
Mean (+ S.E.M.) for the three practolol experiments =
0/97 (+ 0.08) x 10 ' 4  M.
As indicated (Table 15) Salbutamol was noted to be more potent than 
practolol in displacing radioligand off receptor sites implicating beta- 
2 receptors as the major receptor subtype in this tissue (see later).
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Figure 26:
■
■
-6  -5  -4  -3
Log [Practolol (M)]
Representative competition curve using Practolol as cold 
ligand.
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Figure 27:
This representative 1 site fit competition curve was generated 
using (+) timolol maleate as competing cold ligand.
The for this experiment = 2.00 x 10"^ M.
Two other competition experiments were performed using (+) timolol 
maleate as cold ligand.
Kj' for the second experiment = 1.03 x 10”^ M. 
for the third experiment = 1.16 x 1 0 "^ M.
The mean value for the three (+) timolol experiments were:
1.40 (+ 0.30) x 10~ 5 H.
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Figure 27: Representative 1 site fit competition curve using (+)
timolol maleate as competing cold ligand.
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Figure 28:
This representative 1 site fit competition curve was generated 
using betaxolol hydrochloride, a beta-^ blocker as cold ligand. This
study was performed on the same membrane preparation as figure 29.
£
The for this displacement curve = 6.87 x 10 M.
A repeat competition study revealed a 1 site fit for betaxolol 
hydrochloride = 5.89 x 10"^ M.
Mean for the two betaxolol hydrochloride studies =
6.39 (+ 0.50) x 10 " 6 M.
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Figure 28 : Representative competition curve for betaxolol
hydrochloride. Each point is the mean of duplicate 
preparations.
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Figure 29:
This representative 1 site fit competition curve was generated
using ICI 118551 (a beta-2 blocker) as cold ligand. This experiment was
performed on the same membrane preparation as figure 28. ICI 118551 
125displaced [ I]-HYP potently off ciliary process membrane receptors.
o
Recfit analysis of the data revealed a for this drug = 2.78 x 10 M.
A repeat experiment using ICI 118551 revealed another 1 site fit 
with a of 5.53 x 10”®M.
Mean for the 2 experiments = 4 . 6 5  (+ 0.81) x 10"^ M.
As indicated on table 15, the beta-2 blocker ICI 118551 displaced 
radioligand much more potently than betaxolol hydrochloride (beta- 1  
blocker) off the same receptor preparations. This result indicates that 
beta - 2 receptors are the major receptor subtype in this tissue.
-8 - 7  - 6
Log [ICI (M)]
- 5 - 4
Figure 29: Representative 1 site fit competition curve using ICI 
118551 as cold ligand. Each point is the mean of 
duplicate preparations.
Figure 30:
This representative 1 site fit competition curve was generated 
using (-) metoprolol (a beta - 1  blocker) as cold ligand.
The for this (-) metoprolol experiment = 2.1 x 10 M.
Two other similar experiments were performed. Both were 1 site
fits.
_ c
from the second experiment = 1.03 x 10 M. 
from the third experiment = 1.06 x 1 0 ’% .
Mean for (-) metoprolol (+ S.E.M.) = 1.39 (+ 0.3) x 10"^ M.
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Figure 30: Representative competition curve using (-) metoprolol as
competing ligand. Each point is the mean of duplicate 
preparations.
Figure 31:
This representative 1 site fit competition curve was generated
using IPS 339 (beta-2 blocker) as cold ligand. As indicated IPS 339
125potently displaced [ ]I-HYP off cilliary process receptor sites.
for IPS 339 was 1.03 x 10"^ M.
Two further experiments were performed with IPS 339. Both produced 
1  site fit competition curves with values of:
8.31 x 10" 8 M and 
5.9 x 10" 8 M.
Mean results for the three experiments using IPS 339 (+ S.E.M.) = 
8.16 (+ 1.27) x 10" 8 M.
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Figure 31: Representative 1 site fit competition curve for IPS 339.
Figure 32:
This representative 1 site fit competition curve was generated 
using the beta-2 blocker LI 32-468.
This drug potently displaced hot ligand off ciliary process 
membrane receptors.
Reefit analysis revealed a = 3.112 x 10~ 8 M.
Two repeat experiments were performed with LI 32-468. Both produced 1
o
site curves with values of: 2.876 x 10 M and
2.75 x 10‘ 8 M.
Mean (+ S.E.M.) for the three experiments using LI 32-468 =
2.91 (+ 0.10) x 10' 8 M.
Non-specific binding for all previous experiments ranged between 25 
- 45%.
Table 15: This table reviews all the competition data with cold
ligands in rank order of potency. As indicated (-) 
propranolol was the most potent drug. The three beta-2 
blockers all bound potently to ciliary process beta 
receptors while the beta - 1  blockers bound less potently 
to ciliary process beta receptors. Practolol (a beta-1 
blocker) was the least potent of the 1 0  drugs studied.
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Figure 32: Representative 1 site fit competition curve using LI 32-
468 as cold ligand.
134
Drug
No. of
Experiments
Type of 
Adrenergic Drug
(M) value 
(+ S.E.M.)
1 ) (-) Propranolol 3 N.S.B. 1 . 2 0  x 1 0 " 8 (+ 0 .1 2 )
2 ) LI 32-468 3 b 2 2.91 x 10 ’ 8 (+ 0.10)
3) ICI 118551 2 b2 4.65 x 10 ' 8 (+ 0.87)
4) IPS 339 3 b 2 8.16 x 10" 8 (+ 1.27)
5) (+) Propranolol 3 N.S.B. 3.4 x 10 ' 7 (+ 0.31)
6 ) Betaxolol
Hydrochloride
2
B 1
6.39 x 10" 6 (+ 0.50)
7) (-) Metoprolol 3
B 1 1.39 x 10 ‘ 5 (+ 0.3)
8 ) (+) Timolol 
maleate
3 N.S.B. 1.40 x 10 " 5 (+ 0.30)
9) Salbutamolol 3 B.A. 1.99 x 10" 5 (+ 0.50)
1 0 ) Practolol 3
B 1
0.97 x 10 ‘ 4  (+ 0.08)
Table 15: Review of the Competition data in rank order of
potency;
N.S.B. = Non-specific blocker
B-^  = Beta-1 blocker
B 2 = Beta-2 blocker
B.A. = Beta-2 agonist
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Kinetics binding experiments 
I) On rates:
Figure 33: Is a representative KQn computer generated graph.
As indicated, equilibrium was reached within 30 minutes.
KQn for this experiment was:
0.3818 x 109 M " 1  min " 1
Two further KQn experiments were performed.
The results were: on
2) 0.4658 x 109 M " 1 min " 1
3) 0.5115 x 109 M ” 1  min " 1
The mean (+ S.E.M.) KQn for the 3 experiments was 
.4530 (+ 0.037) x 109 M ' 1  min " 1
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Figure 33: Time course of association (KQn) of [ I]-HYP binding to
beta adrenoceptors on cell membranes derived from sheep 
ciliary processes.
Figure 34:
This computer generated graph shows the time course of dissociation 
for 3 separate experiments. The computer derived KQ££ rates were;
I) 1.124 X 1 0 " 1 min"^
II) 9.515 X 1 0 ‘ 2
-1min
III) 1.003 X 1 0 " 1 min"^
Mean KQ££ = 1.026 (+ .051) x 10"^ min"^
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Figure 34: Three (Koff) time course of [X^I]-HYP dissociation
graphs from three separate experiments. Each point is 
the mean of triplicate preparations.
Kq££ = Ln 2/t (Levitzki, 1984) 
1*2 = 0.693 
tl/ 2  = Ln 2/Koff
= 0.693
>-11.026 x 1 0 " min' 
= 6.75 minutes
KD - Koff
on
= 1.026 x 1 0 " 1 min " 1  
0.453 x 10 9 M " 1  min ' 1
Kd - 226 pM
The dissociation constant (K^) determined from the kinetic studies 
is in reasonable agreement with the derived from equalibrium
saturation binding (K^ = 363 pM).
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E) Discussion of Radio-ligand binding results
A major aim of this thesis was to develop a readily repeatable
radioligand method to detect and characterize beta-adrenoceptors derived 
from pigmented iris-ciliary body diaphragm and ciliary processes. The 
technique described in the methods and material section has allowed this 
to be accomplished. There are however aspects which require 
clarification.
1) General discussion on melanin and membrane preparation.
The first major obstacle to overcome was the presence of large
amounts of melanin derived from the pigmented tissue homogenates. 
Melanin binds radioligand thereby increasing non-specific binding (Wax 
and Molinoff, 1987). The melanin problem was eventually overcome by 
removing it from the tissue homogenate by a process of 
ultracentrifugation using a discontinuous sucrose gradient. This 
process removed the melanin to the bottom of the tube enabling membrane
fragments to be collected from the interface.
Membrane fragments were prepared for ligand binding studies using 
the described method. Bromberg et al used homogenised membrane 
fragments and sucrose gradients in their study on the ciliary processes 
(Bromberg et al., 1980). Despite an inadequate washing technique 
Bromberg et al reported maximum ligand binding to cellular fragments at 
the 5:50% interface and presumed the presence of membrane fragments. 
These workers did not study the tissue they were working with by either 
light microscopy or electron microscopy. Our transmission electron 
micrographs confirmed that membrane fragments do indeed collect at this 
5:50% interface.
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It is important to determine the source of these membrane 
fragments. In the preliminary iris-ciliary body experiments they came 
from a combination of ciliary epithelium, iris epithelium, iris and 
ciliary body stroma, neuronal tissue and muscle fibres. However, for 
the ciliary process study the site of origin can be more accurately 
localised. The ciliary processes consist of two layers of epithelium; a 
stroma of collagen fibres, fibroblasts, nerves and a central vascular 
channel (Streeten, 1984). Transmission electron microscopic examination 
of the fragments revealed that they were essentially epithelial in 
origin and as a result the majority came from ciliary epithelium. 
Clearly however, exact localization of beta receptors to the non- 
pigmented epithelium was not proven and has yet to be achieved. Other 
workers have attempted to directly localize beta receptors to the non- 
pigmented epithelial cell walls. In 1979 Dafna et al used a fluorescent 
analogue of propranolol to identify binding sites to anterior segment 
receptors. Most of the binding in this study occurred in the basal 
layer of the non-pigmented epithelium. Some binding to both the 
pigmented epithelium and episcleral vessels however also occured (Dafna 
et al., 1979). There was no mention regarding binding to receptor sites 
in the lateral intercellular spaces. A major problem with Dafna's study 
is the fact that the authors did not consider the problem of non­
specific binding by propranolol. Despite this, their paper still has 
some relevance as a broad indicator of potential beta receptor sites in 
the ciliary processes. Other workers using different techniques have 
tried to localise beta receptors to the non-pigmented ciliary 
epithelium. Recently, an autoradiographic technique was developed to try
to localize these receptor sites, but these results have not been 
verified (Burnstein et al., 1983). Polansky et al have reported a 
method to separate non-pigmented cells from pigmented cells in bovine 
eyes (Polansky et al., 1985). This technique involves dissection of 
ciliary processes, 1  hour incubation in a variety of chemicals and 
gentle vortexing. Apparently non-pigmented ciliary epithelial cells 
eventually separate from the ciliary processes. Perceptable membrane 
damage to cells does however occur. Despite the authors claims that 
there is greater than 95% purity, pigment contamination was significant 
enough for the authors to employ both a centrifugation technique and a 
1 0 / 2 0 % ficoll gradient to get rid of pigment to concentrate membrane 
fragments. Clearly, this technique is very complex with little 
advantage over the method described in this thesis to prepare melanin 
free membrane fragments. Cell cultures of non-pigmented epithelium 
would allow accurate receptor identification. A novel technique has 
recently been described by Coca-Prados et al to culture intact non- 
pigmented epithelial cells from bovine eyes (Coca-prados et al., 1986). 
This technique is a complicated one requiring special plastic substrates 
and hormones and the support of a cell culture laboratory. Carefully 
monitored incubation times are required to weaken the junctional 
complexes (Desmosomes, ga^fjunctions, puncta adherence) that bind the two 
epithelial layers together (Streeten, B.W. 1982, Raviola G. and Raviola, 
E. 1978). Clearly, if this cell culture techniques works and proves to 
be repeatable radioligand studies on pure non-pigmented ciliary 
epithelium will allow for accurate anatomical localization of beta 
adrenoceptors.
Once melanin contamination was eliminated from the sample and T.E.M. 
of the interface of the sucrose gradient confirmed the presence of 
membrane fragments the problem then arose as to which radio-ligand 
method to use to investigate beta-receptors in anterior segment tissues. 
The technique described by Bromberg et al using specific numbers of 
droplets from punctured sucrose gradient tubes without a filtration or 
washing step proved unrepeatable on pigmented tissue in our hands. As a 
result a more conventional binding method was developed using a 
homogenization technique, density gradient ultra-centrifugation and the 
accurate transfer of membrane fragments to sample tubes as described in 
the methods and materials section of this thesis. Standard filtration 
and washing techniques were used in this study (Burt 1985, Titinchi 
1984, Nahorski et al., 1978). Temperature control of water baths,
tissue preparations and incubation times were systematically optimized 
as the experiments progressed.
2) Discussion of Preliminary Results on Iris Ciliary Body 
Diaphragm
Mean Bmax for the preliminary iris ciliary body experiments was 
97.45 fmol/mg with a of 130 pM. The stereospecificity competition 
curve performed on iris-ciliary body diaphragm, (Fig. 18) revealed Ki 
values for the two stereoisomers of Propranolol that differed by a 
factor of 75, which is typical of functional beta-receptors. As 
indicated in the characterization experiment a predominance of beta - 2  
receptors (+ 80%) were detected on computer analysis of the data. This 
result suggests that beta- 1  receptors must have arisen from the iris
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and non-epithelial parts of the ciliary body, as later experiments 
revealed all beta receptors in the ciliary processes to be of the beta - 2  
sub-type.
A number of different workers have attempted to study beta 
receptors in iris ciliary body diaphragm. Page and Neufeld reported a 
Bmax of 330 fmol/mg protein and a Kp of 2.4 nM from albino rabbit iris
3
ciliary body tissue homogenates using H-dihydroalprenolol as 
radioligand (Page and Neufeld, 1978, Neufeld et al., 1978, Neufeld and 
Page, 1977). It is important to note however, that these authors did 
not show graphic proof of saturation of beta receptors and scatchard 
analysis or stereospecificity graphs of their data. Bhargava et al, 
reported a Bmax of 960 fmoles/mg protein and a of 700 nM in pigmented 
monkey iris ciliary body homogenates (Bhargava, 1980). No attempt was 
made to remove melanin from the tissue homogenates by these authors. As 
a result further discussion of their work is not helpful.
Schmitt et al., recently reported data on Albino rabbit iris- 
ciliary body diaphragm (Schmitt et al., 1984). These authors reported a 
Bmax of 272 fmol/mg protein, and a Kq of 1.2 nM. These authors 
presented data supporting the view that beta- 2 receptors are the major 
receptor sub-type in this tissue. As indicated by Clark et al., 
Schmitt's paper suffers from a variety of weaknesses (Clark et al., 
1985). The major concern relates to Scatchard analysis of the binding 
data. No saturation curves and scatchard graphs were presented and no 
stereospecificity or kinetic data were reported. A variety of other 
concerns exist with regard to this paper, all of which have been 
summarized by Clark et al., (Clark et al., 1985). Mittag and Tormay
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recently published data on New Zealand rabbit iris ciliary body 
diaphragm. These authors reported a Bmax of 132 fmol/mg protein with a 
Kp of 0.6 nM. Stereospecificity and kinetic studies however, were not 
performed by these authors. They conclude however, (from two 
competition curves using epinephrine and norepinephrine) that beta - 2  
receptors are the major receptor sub-types in rabbit iris ciliary body 
(Mittag and Tormay, 1985).
Wax and Molinoff recently published binding data on human iris
ciliary body diaphragm. These authors confirmed the importance of
removing melanin from tissue homogenates and make reference to our
sucrose gradient technique. Wax and Molinoff, used a 20% percoll
gradient for this purpose and reported a Bmax of 134 fmol/mg and a of 
106 pM. They also detected beta-2 receptors in iris ciliary body
diaphragm and reported that 1 0 % of beta receptors were of the beta - 1
subtype. (Wax and Molinoff, 1987). These results are very similar to
our preliminary data derived from sheep iris ciliary body diaphragm.
3) Discussion of results on ciliary processes
The major purpose of this section of the study was to determine 
whether beta-adrenoceptors exist in ciliary process and to determine 
their subtype.
Our experiments revealed a mean Bmax of 98 fmol/mg protein with a 
mean of 363 pM. Our data was the first radioligand data published on 
ciliary processes (Trope and Clark, 1982). Three studies have
subsequently reported saturation binding data on ciliary processess. 
Elena et al., published their binding data in 1984. These authors, used 
homogenized bovine tissue as their source of membranes (Elena et al.,
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1984). The major difference in technique was the use of a 45,000 g spin 
for 30 minutes using a 40% percoll density gradient to separate melanin 
from membrane fragments. These authors confirmed the presence of 
saturable beta-adrenoceptors in bovine ciliary processes. Bmax was 1.28 
pmol/mg protein with a Kq of 320 pM. The K^'s between the two studies 
are very similar, i.e., 320 pM versus 363 pM in our study. A problem
with Elena study is the reported Bmax. These authors indicated a Bmax 
of 1.28 pmol/mg protein which is significantly different from that found 
in our sheep eyes (Bmax = 98 fmol/mg protein). Their Bmax level is also 
inconsistant with levels reported in other tissues (Mimmeman et al., 
1979). Elena et al., have attributed the Bmax difference mainly to 
species differences (Elena et al., 1984).
Polansky et al., reported their results in 1985. Using tissue 
preparative technique described earlier, their reported saturation 
results are similar to ours namely Bmax of 43 fmol/mg protein and a 
of 216 pM (Polansky et al., 1985). These authors however did not 
indicate the concentration of radio-ligand used in their binding 
experiments, nor did they graphically document their saturation data.
Wax and Molinoff have recently reported saturation binding data 
derived from human ciliary process membrane preparations (Wax and 
Molinoff, 1987). Their paper reports a Bmax of 180 fmol/mg protein and 
a Kq of 92 pM. Differences in technique include the use of a percoll 
density gradient and the use of [^**1]-iodopindolol. ( [ ^ ^ 1 ] -IPIN) .
Furthermore they used 200 nM (-) timolol maleate to determine non­
specific binding. Despite the species and technical differences, the 
data derived from both our studies are similar (See later).
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The kinetic results reported in this thesis support the view that 
beta-adrenoceptors exist in ciliary processes of sheep eyes. The 
derived from kinetic studies was similar to the derived from direct 
saturation binding studies on ciliary process membrane fragments. 
Kinetic studies have been reported by Elena et al and Wax and Molinoff 
(Elena et al, 1982; Wax and Molinoff, 1987). Elena et al reported that 
equilibrium was reached in 60-70 minutes. Wax and Molinoff however, 
reported that in human tissue equilibrium was reached around 2 0  minutes;
similar to our study. The KQn and KQ££ results reported by Wax and
Molinoff are similar to our results. These authors reported KQn data of 
2.7 x 10^ M"^ min"^ (0.45 x 10^ M"^ min"^) and KQ££ values of 1.8 x 10“^
_ i _ _ i
min with a tjy2 min. (1.026 x 10 min , t-jy2 = 6.75). Our
results are in parenthesis.
Stereospecificity data has been reported on bovine ciliary
processes by both Elena et al., and Polansky et al., (Elena et al.,
1984, Polansky et al., 1985). Polansky reported an IC^q for (-) and (+)
- 9 - 6propranolol of 2 x 10 M and 1 x 10 M respectively. Elena reported
Ki values of 3.4 x 10"^ M for (-) propranolol and 6.275 x 10"^ M for (+)
propranolol. In our series of ciliary processes competition experiments 
(-) propranolol was the most potent of all beta-blockers (K-^  = 1 . 2  x 1 0 “
Q
M) (Table 15). Our K^ value for (-) propranolol was an order of
magnitude larger than that reported by Elena and Polansky. The Ki value
for (+) Propranolol was similar to Elena's reported value but one order
of magnitude smaller than Polanskys value.
It is interesting to note that two years after we published our 
preliminary competition data on sheep ciliary processes, (Trope et al.,
1982) Elena et al., published their competition curves derived from
bovine eye experiments confirming our data that beta - 2 receptors are the
major receptor subtype in the ciliary processes. Elena et al., reported
a Ki value for IPS 339 of 8.16 x 10"® M which is similar to our Ki value 
-  8(2.8 x 10 M) . Elena et al., however did not study any other beta-2 
blockers (Elena et al, 1984). 5 years after our report Wax and Molinoff
confirmed our results in human eyes. These authors reported that the 
beta-2 blocker ICI 118551 inhibited radioligand binding 56 times more 
potently than the beta-1 blocker ICI 89406. As indicated on table 15, 
ICI 118551 displaced ['^"’ij-HYP 137 times more potently than the beta-1 
blocker betaxolol hydrochloride. Wax and Molinoff also reported that 
their competition curves fit best to a 1 site fit. Probably due to the 
tedious nature of preparing large enough quantities of ciliary process 
membrane preparations, they did not report IC^q or K- values for any 
other beta-2 or beta-1 blockers (Wax and Molinoff, 1987).
There is other data to support our findings that beta-2 receptors 
exist in the ciliary processes. In 1980 Nathanson reported for the 
first time that beta- 2 agonists maximally stimulated the production of 
cyclic AMP in animal and human ciliary processes (Nathanson, 1980). 
This has been confirmed by Cepelik et al. and Elena et al. , (Cepelik et 
al., 1981; Elena et al., 1984).
In conclusion, I  report that beta adrenoceptors exist in sheep 
ciliary processes and that they are of the beta-2 subtype. Our binding 
results have very recently been confirmed by studies on human ciliary 
processes (Wax and Molinoff, 1987).
The next goal of this study was to apply these in vitro results to 
the in vivo situation. Specifically, we wished to determine whether 
beta-2 antagonists inhibit aqueous production and lower 1.0.P. However, 
a number of developmental experiments were first performed (as indicated 
in the next subsection) before this major aim was undertaken.
II) Development of techniques used to study intra-ocular 
pressure recovery rate and intra-ocular pressure in rabbits with 
glaucoma.
A) Pneuma-tonometer Calibration
I) For the in vivo animal studies a Digilab pneuma-tonometer was 
used to measure rabbit intra-ocular pressure. As this instrument is 
calibrated for use in humans (Langham and McCarthy, 1968) (Quigley and 
Langham, 1975) it was decided to perform calibration studies on rabbit 
eyes before using this instrument to determine intra-ocular pressure 
recovery rate and intra-ocular pressure measurements in buphthalmic 
rabbits.
The pneuma-tonometer is an applanation tonometer developed by 
Langham et al. in 1968 (Langham and McCarthy, 1968). It incorporates a 
tonometric probe, a pressure transducer and a digital readout of intra­
ocular pressure. The probe contains a hollow plunger that rides on a 
porous sleeve. A gas (Dichlorofluomethane (CCI2 F2 )) flows through the 
plunger to the specialized tip and through the wall of the porous sleeve 
to form an "air bearing". The gas pressure pushes the plunger outward. 
When the tip is applied to the cornea, gas escape is impeded from the 
specialized tip causing the gas pressure to rise. This pressure rise
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causes the plunger and tonometer tip to propel . forward with greater 
force until flow of gas resumes. The force required to resume gas flow 
is measured and according to instrument design is converted to mmHg 
(Moses and Grodzki, 1979). Moses and Grodzki have suggested that the 
instrument does indent the cornea somewhat so it should be considered to 
be both an applanation and identation tonometer (Moses and Grodzki, 
1979).
As previously indicated, the pneuma-tonometer is calibrated for 
human use. To ensure that the instrument reflected accurate readings on 
rabbit eyes we calibrated the Digilab pneuma-tonometer by using a 
computerized miniturized universal pressure meter as our standard.
1) Methods and Materials:
1) To ensure that our standard universal pressure meter was 
accurate, it was initially tested against a mercury manometer. 
Pressures from 10 mm of mercury to 100 mm of mercury were tested. A 
constant error of -2 mm of mercury was detected. This constant error 
was eliminated by the addition of 2  mm of mercury to all measurements.
2) A 25 gage needle was connected to PE 160 polyethylene tubing 
to one of the stopcock valves attached to the universal pressure meter.
3) A 20 cc syringe was connected to the other stopcock valve.
4) The system was filled with 0.9% saline, all air bubbles were 
carefully removed and the stop cock closed.
5) A brown pigmented rabbit was anesthetized with Sodium
Pentibarbital (35 mg/Kg) intravenously.
6 ) The rabbits right eye was positioned under the surgical
microscope and a lid speculum used to retract the lids. Topical 
anesthetic was administered to the eye.
7) The anterior chamber was canulated with the 25 gauge needle
throught the limbus along the iris plane.
8 ) Measurements with the pressure meter were then made with the 
stopcock closed (Varelles et al., 1977). Simultaneous measurements were 
made with the pneuma-tonometer applied to rabbit cornea. Four more 
readings were taken in the same fashion with the mean of the results 
taken as the final IOP.
9) The intra-ocular pressure in the rabbit eye was then
artificially raised between 10 to 45 mm of mercury. This was 
accomplished by opening the stopcock valve to which the saline filled
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syringe was connected. Saline was then injected directly into the eye 
under direct visualization throught the microscope. When the anterior 
chamber was noted to be deep, the stopcock was closed and the pressure 
measured simultaneously with the universal pressure meter and pneuma- 
tonometer. As the I.O.P. declined, approximately 10 intra-ocular 
pressure readings were taken with both the universal pressure meter and 
pneuma-tonometer. This procedure was then repeated on the second eye of 
the rabbit and again repeated on the two eyes of a second rabbit. A 
total of 35 readings were taken. The results were plotted graphically.
After the experiment was completed the rabbits were given an 
overdose of anesthetic.
Table 16 documents materials used in the above experiments.
Results:
Figure 35 shows the computer generated correlation graph of the 
pneuma-tonometer versus the universal pressure meter under closed 
stopcock conditions. Pressures were measured within the range of 10 - 
45 mm of mercury. The result was a straight line with a correlation 
coefficient of 0.97. The equation of the regression line was y = 0.821 
+ 0.859X.
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1) Universal pressure meter - Bio Tech (DPMII) Instruments, U.S.A.
2) Pneuma-tonometer - Digilab Model 301, Cambridge, MA., U.S.A.
3) Surgical Microscope - Zeiss, West Germany.
4) 3 way stopcock
5) Polythyene tubing (PE 160).
6 ) Sodium pentibarbital - "Somnotol11 - MTC pharmaceuticals, 
Mississauga, Canada.
7) Proparacane Hcl (0.5%) topical eye drops - Allergan Inc., Quebec, 
Canada.
8 ) 2 pigmented Rabbits (3.2 and 3.6 Kg).
Table 16: Materials used to calibrate pneuma-tonometer
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Figure 35: Comparative tonometric measurements of a digilab pneuma -
tonometer vs universal pressure meter. Data eerived from 
4 experiments.
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y = 0.812 + 0.859 x R = 0.97
2) Discussion:
The purpose of this experiment was to calibrate the Digilab pneuma- 
tonometer for use on rabbit eyes.
For intra-ocular pressures ranging between 10 to 45 mm of mercury a 
tight linear relationship was found between tonometric measurements (y) 
and the standard universal pressure meter (x) as reflected by the high 
correlation coefficient (R == 0.97).
In conclusion the pneuma-tonometer appears to be a good instrument 
for measuring intra-ocular pressure in rabbit eyes. In rabbits with 
normal IOP's (as used in our intra-ocular pressure recovery experiments) 
the pneuma-tonometer will produce very accurate I.O.P. measurements. 
The slightly greater scatter at higher I.0.P.'s indicates the instrument 
is slightly less accurate for use in rabbits with raised I.O.P. but as 
most rabbits with glaucoma do not have pressures above 35 mm of mercury, 
the instrument is both reliable and precise for use in such animals.
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B) I.O.P. Recovery Technique Development and Discussion
Once the pneuma-tonometer was calibrated we performed a control
experiment to determine intra-ocular pressure recovery in 6 rabbits.
Methods & Materials:
6 Pigmented rabbits underwent the I.O.P. recovery test as outlined
in the Materials and Methods section, except that phosphate Buffer (pH
7.4) was randomly placed on 1 eye of each rabbit and nil in the second
eye of each rabbit.
Results:
I.O.P. recovery rate for the
1) Untreated eyes was: 0.13346 + .01588 mmHg/minute^
2) Buffer treated eyes: 0.14121 + 0.006541 mmHg/minute^
There was no statistical difference in the slopes of these 2 lines
(p < 0.3). The buffer values were used as the controls in later
experiments.
Figure 36: This figure reveals the slopes of the 2 lines. It
indicates that intra-ocular pressure recovered to its 
original I.O.P. within 140 minutes. Each reading is the 
mean (+ S.D.) I.O.P.
Discussion: This first recovery rate experiment provided control
values and confirmed the feasibility of using the intra-ocular pressure 
recovery rate experiments as an indirect method of measuring aqueous 
production. The results of this control experiment were similar to 
published data (Varielles and Lotti, 1981). These same 6 rabbits were 
later used for the I.O.P. recovery rate experiments.
The next section of the thesis contains the results of the in vivo 
studies.
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Figure 36: Effect of buffer vs nil treatment on I.O.P. recovery rate
(aqueous humour index) in 6 unanaesthetised normal 
rabbits.
(Dotted Line = Buffer treated eyes).
(Solid Line = Nil treated eyes).
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RESULTS
The results section of this thesis contains the results of studies 
to determine; 1 ) the effects of beta- 2 blockers on aqueous production 
and 2) the effects of beta-2 blockers on I.O.P. in rabbits with 
glaucoma.
I) Results of the Intra-ocular Pressure Recovery Rate Experiments
(Aqueous Humour Index)
Figure 37: This figure compares the mean (+ S . D .) effect of the
beta-2 blocker IPS 339 vs buffer on intra-ocular pressure recovery rate.
IPS 339 significantly inhibited intra-ocular pressure recovery rate 
compared to the buffer treated group of eyes (P < 0.0042). IPS 339
produced a 44.54% mean inhibition of intra-ocular recovery rate in the 
drug v s . buffer treated eyes.
The intra-ocular pressure recovery rate was inhibited by 66.15% in 
the treated vs the control group of rabbit eyes (P < 0.0001) indicating 
that IPS 339 inhibited I.O.P. recovery in the buffer treated group of 
second eyes (consensual effect) (Table 17) (See discussion).
IPS 339 had minimal effect (over 50 minutes) on normal rabbit
I.O.P. as evidenced by the + 1 mm Hg drop in mean I.O.P.
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Figure 37: Effect of IPS 339 vs. buffer on intra-ocular pressure
recovery rate.
Figure 38:
This figure compares the mean (+ S.D.) effect of LI 32-468, another 
Beta-2 blocker, with buffer on intra-ocular pressure recovery rate.
LI 32-468 significantly inhibited intra-ocular pressure recovery 
rate compared to the buffer treated group of eyes (P < 0.0042). There
was a 41.68% mean inhibition of intra-ocular pressure recovery in the 
drug vs. the buffer treated eyes (Table 17).
The intra-ocular pressure recovery rate was inhibited by 61.10% in 
drug treated vs the control group of rabbit eyes (P < 0.0001) (Table 17) 
indicating a consensual effect of the drug on the buffer treated second 
eyes (see discussion).
LI 32-462 also produced minimal effect on normal rabbit I.O.P. 
There was less than a 1 mm Hg mean drop in I.O.P. over the 50 minute 
time period before infusion of hypertonic saline.
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Figure 38: Effect of LI 32-468 vs. buffer on intra-ocular pressure
recovery rate.
Figure 39:
This figure compares the effect of ICI 118551, with buffer on 
intra-ocular pressure recovery rate.
As indicated, ICI 118551 inhibited mean intra-ocular pressure 
recovery rate compared to the buffer treated group of eyes. There was a 
mean inhibition rate of 21.61% in the drug vs. buffer treated eyes. 
This difference however, was not statistically significant (P < 0.178).
ICI 118551 however had a marked consensual effect on I.O.P. 
recovery as evidenced by a 58.99% inhibition of intra-ocular pressure 
recovery rate in the drug treated vs. the control group of eyes. (P <
0.0001) (Table 17). Furthermore, the group of buffer treated second 
eyes had the slowest intra-ocular pressure recovery rate of all the 
buffer groups treated (0.07404 mmHg/min"^ + 0.04359) (Table 17) (See 
discussion).
As with the previous two beta-2 antagonists drugs, ICI 118551 had 
minimal effect on normal rabbit mean I.O.P. over the 50 minute period 
before administration of the hypertonic saline.
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Figure 39: Effect of ICI 118551 vs. buffer on Intra-ocular pressure
recovery rate.
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Figure 40:
This figure compares the effect of commercially available (-) 
timolol maleate (Timoptic 1/2%) with buffer on intra-ocular pressure
recovery rate in normal rabbit eyes.
(-) timolol maleate significantly inhibited intra-ocular pressure 
recovery rate compared to the buffer treated group of second eyes (P <
0.05). There was a 26.86% mean inhibition of intra-ocular pressure
recovery rate in the drug v s . buffer treated eyes.
Like the other drugs (-) timolol maleate also appeared to have a 
significant consensual effect. There was a 49.97% inhibition of rabbit 
intra-ocular pressure recovery rate in the drug vs the control group 
of rabbit eyes. (P < 0.0001) Like the other drugs (-) timolol maleate 
had minimal effect on normal rabbit I.O.P. before administration of the
1.V. hypertonic saline.
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Figure 40: Effect of timolol maleate vs. buffer on rabbit intra­
ocular recovery rate.
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Figure 41:
This figure compares the effects of commercially available 0.5% 
betaxolol hydrochloride (Betoptic) a beta-1 specific blocker, with 
buffer on rabbit intra-ocular pressure recovery rate.
Betaxolol had a small but not statistically significant effect on 
the drug vs. buffer treated group of eyes. (7.81% inhibition) (P < 
0.5656).
Betaxolol hydrochloride did however, have a consensual effect as 
evidenced by a 41.74% inhibition in intra-ocular pressure recovery rate 
in the drug vs. control group of eyes (Table 17) (P < 0.0002).
Table 17 indicates that betaxolol hydrochloride significantly 
inhibited aqueous production but had the weakest effect on intra-ocular 
pressure recovery rate of the five drugs tested (See discussion). As 
with the other drugs betaxolol hydrochloride had minimal effect on mean
I.O.P. before infusion of the hypertonic saline.
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Figure 41: Effect of betaxolol hydrochloride vs. buffer on intra­
ocular pressure recovery rate.
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Table 17:
This table details the results (mean + standard deviation) and 
statistical significant of the intra-ocular pressure recovery rate 
experiments in order of potency. As indicated the Beta-2 blockers IPS 
339 LI 32-468 and ICI 118551 were the most potent of the five drugs 
tested. These three Beta-2 blockers inhibited I.O.P. recovery by 
66.15%, 61.10% and 58.99% respectively. (-) timolol maleate inhibited
I.O.P. recovery by 49.97% while the B-^  blocker betaxolol HC1 (Betoptic) 
inhibited I.O.P. recovery by 41.74%.
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Slope of I.O.P. 
Treatment recovery rate 
(mm Hg/min )
% Difference p % Difference p 
between drug Value between drug Value 
v s . buffer v s . control
1) IPS 339 0.0478 + 0.003457 -44.54%
Buffer 0.0862 + 0.005457
Control 0.14121 + 0.006541
0.0042 -66.15% 0.0001
2) LI 0.05493 + .008201 -41.68%
Buffer 0.09418 + 0.008201
Control 0.14121 + 0.006541
0.0042 -61.10% 0.0001
3) ICI 0.05804 + 0.00435 -21.61%
Buffer 0.07404 + 0.004359
Control 0.14121 + .006541
0.1782 -58.99 0.0001
4)(-)Timolol 0.07065 + .006601 -26.86% 
Maleate
Buffer 0.0966 + .006601
Control 0.14121 + .006541
5)Betaxolol 0.08227 + 0.004638 -7.81%
HC1
Buffer 0.0893 + 0.004638
Control 0.14121 + 0.006541
0.0535 -49.97 0.0001
0.5656 -41.74 0.0002
Table 17: Results (mean + standard deviation) of I.O.P. recovery
rate (aqueous humour index) of drug treated, buffer 
treated second eyes and control group of rabbit eyes.
% difference = slope of drug - slope of buffer or control x 1 0 0
slope of buffer or control 1
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II. Effect of Beta-Blockers on Intra-Ocular Pressure in Buphthalmic 
Rabbits
Figure 42: This figure documents the effects of 50 ul of 1% IPS 339
on glaucoma rabbit intra-ocular pressure.
As indicated mean intra-ocular pressure dropped from 26 mm Hg to 20 
mm Hg ( - 6  mm Hg) (23%) within one hour of topical application of 50 ul
1% IPS 339. The initial change in intra-ocular pressure over the first
2 hours was statistically significant when compared to the Diurnal 
control group of glaucoma eyes (P < 0.02).
This drop in intra-ocular pressure was sustained over the 2 - 12 
hour period of the study with a final intra-ocular pressure reading 16.5 
mm Hg. The contrast between the treated and control group of eyes was 
statistically significant over the 2 - 1 2  period (p < 0 .0 0 0 1 ).
Table 18: This table reviews the mean I.O.P. (+ S.D.) readings for
the treated and diurnal control eyes.
Figure 43: This figure documents the consensual effect of 1% IPS 339.
As indicated IPS 339 was systemically absorbed and dropped mean I.O.P.
from 31.5 mm Hg to 24.5 mm Hg (22.2%). Statistical analysis of the data 
revealed that there was no statistically significant difference between 
the IPS treated and the untreated fellow eyes over the 0-12 hr period 
of the study (p < 0.75).
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Figure 42: Effect of 50 uls of 1% IPS 339 on Buphthalmic treated
eyes. Each point represents the mean I.O.P. of 5 rabbit 
eyes.
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Time IPS 339 Control S.D.
Treated IOP S.D. Group (mm Hg) (mm Hg)
(mm Hg) (mm Hg)
0 26 6.3 26.8 4.8
15 mins 23.2 8 . 2 N/T
30 mins 20.9 5.4 N/T
45 mins 2 0 . 0 5.6 N/T
60 mins 20.5 7.1 27.5 4.1
1  1 / 2  hrs 2 0 . 1 6.4 N/T
2 hrs 20.7 6 . 2 28.5 3.1
3 hrs 18.1 6 . 0 26.2 1.5
4 hrs 20.5 6.7 26.2 3.3
5 hrs 17.8 6.7 27.2 4.3
6 hrs 18.8 5.4 25.6 5.6
7 hrs 19.4 4.4 27.6 4.2
8 hrs 18.7 5.7 27.0 5.0
9 hrs 18.8 6.7 29.2 4.5
1 0  hrs 17.5 5.7 29.1 3.8
1 1  hrs 17.4 6 . 0 28.4 3.7
1 2  hrs 16.5 5.1 28.8 3.9
Table 18: Mean intra-ocular pressure ((+) S.D.) for
treated eyes and diurnal control eyes over the 1 2  hour 
period of the study.
N/T = Not tested.
173
IO
P 
( 
mm
 
Hg
)
26 4
24 4
r ~
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
TIME (hrs)
Figure 43: Consensual effect of a 50 ul drop of 1% IPS 339.
point is the mean I.O.P. of 5 rabbits eyes.
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Figure 44:
This figure documents the effect of 50 ul of 1% LI 32-462 on 
glaucoma rabbit intra-ocular pressure.
As indicated mean intra-ocular pressure dropped 21.8% in the 
glaucoma eyes from 31.6 mm Hg to 24.7 mm Hg (-6.9 mm Hg) with in the 
first hour post treatment. The initial change in intra-ocular pressure 
over the first 2 hours was statistically significant when compared to 
the diurnal control group of eyes (p < 0 .0 2 ).
This decrease in intra-ocular pressure was sustained over the 2 
12 hour period of the study. The final intra-ocular pressure reading 
was 19.8 mm Hg at 12 hours. The contrast between the L132-468 treated 
and the control group of eyes was statistically significant over this 2  
- 1 2  hour period of the study (p < 0 .0 0 0 1 ).
Table 19: This table Documents the actual (mean + S.D.) intra­
ocular pressures in the LI 32-468 treated and the 
diurnal control treated eyes over 1 2  hours.
Figure 45: This graph illustrates the consensual effect of LI 32-
468. As indicated one hour post treatment the mean intra-ocular 
pressure dropped from 33 mm Hg to 28 mm Hg (15%) in the untreated second 
eyes. Over the first 2 hours there was no statistically significant 
difference between the intra-ocular pressure in the treated and
untreated eye (p < 0.06). Over 2 - 1 2  hours however, LI did not lower 
intra-ocular pressure in the untreated eye as significantly as in the 
treated eye. The contrast between the 2 eyes at this time was
significantly different (P < 0.0001).
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Figure 44: Effect of a 50 ul drop of 1% LI 32-68 on buphthalmic
rabbit intra-ocular pressure. Each point is the mean
I.O.P. reading taken from 5 rabbit eyes.
Time LI 32-468
Treated eyes S.D. Control eyes S.D.
(mm Hg) (mm Hg) (mm Hg) (mm Hg)
0 31.6 6 . 2 26.0 6.3
15 mins 26.2 6 . 0 N/T
30 mins 24.1 6 . 0 N/T
45 mins 2 2 . 0 6 . 0 N/T
60 mins 24.7 5.0 25.5 6.7
1  1 / 2  hrs 24.7 3.0 N/T
2 hrs 25.6 1 . 8 26.6 7.3
3 hrs 24.5 5.2 25.3 6.5
4 hrs 18.6 8.4 26.4 6.5
5 hrs 21.9 4.4 24.3 9.8
6 hrs 22.9 4.6 24.6 6 . 0
7 hrs 2 1 . 2 4.3 24.6 6 . 8
8 hrs 2 1 . 1 4.0 25.9 7.1
9 hrs 18.2 5.3 27.5 5.1
1 0  hrs 19.8 5.0 25.9 3.6
1 1  hrs 19.8 5.6 25.2 3.2
1 2  hrs 19.8 5.4 25.6 6 . 2
Table 19: Mean (+ S.D.) intra-ocular pressures for LI 32-468
treated eyes and diurnal control eyes over 1 2  hours.
N/T = Not tested.
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Figure 45: Consensual effect on mean I.O.P. of 50 ul of LI 32-468.
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Figure 46:
This figure documents the mean intra-ocular pressure drop in the 
ICI 118551 treated eyes, untreated second eyes and diurnal control eyes. 
As indicated mean intra-ocular pressure dropped 16.6% in the drug 
treated eyes from 24 mm Hg to 20 mm Hg (4 mm Hg) over the first hour of 
the study. The contrast between the drug treated and control eyes over 
the first 2 hours of the study was statistically significant (P < 0.01). 
This effect was sustained over the 12 hour period of the study (P < 
0.001). This figure also indicates that ICI 118551 was systemically 
absorbed and had a consensual effect. There was no statistical 
differences between the treated and the untreated eyes over both the 0  - 
2 and 2 - 12 hr period of the study (P <0.06) indicating both a short 
and long term systemic effect.
Table 20: This table documents the actual intra-ocular pressures in
the drug and diurnal control group of eyes.
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Figure 46: Direct and consensual effect of a 50 ul drop of 1% ICI
118551 on buphthalmic rabbit intra-ocular pressure. Each 
point represents the mean I.O.P. of 5 rabbit eyes.
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Time ICI 118551
Treated eyes S.D. Control eyes S.D.
(mm Hg) (mm Hg) (mm Hg) (mm Hg;
0 23.917 + 3.8 24.83 5.22
15 23.167 + 4.622 NT
30 22.417 + 3.666 NT
45 21.333 + 4.309 NT
1  hr 20.167 + 4.803 NT
1  1 / 2  hrs 21.333 + 4.082 24.42 5.60
2 hrs 20.583 + 4.03 23.67 5.09
3 hrs 19.833 + 3.869 22.83 4.89
4 hrs 20.167 + 6.274 23.00 4.43
5 hrs 20.083 + 4.652 20.67 6 . 6 8
6 hrs 20.167 + 3.642 21.92 4.31
7 hrs 18.667 + 3.817 21.67 4.27
8 hrs 20.083 + 3.121 22.08 4.63
9 hrs 20.750 + 3.029 25.08 4.72
1 0  hrs 20.250 + 2.752 24.00 2.19
1 1  hrs 19.500 + 2.280 23.17 2 . 1 1
1 2  hrs 19.750 + 2.162 22.83 2.72
Table 20: Effects of 50 ul of 1% ICI 118551 on glaucoma rabbit
intra-ocular pressure.
NT = not tested.
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Figure 47:
This figure documents the effects of 50 ul of 1/2% (-) timolol
maleate (Timoptic) on glaucoma rabbit intra-ocular pressure.
As indicated mean intra-ocular pressure dropped 23.3% from 34.3 mm 
Hg to 25.7 mm Hg over the first hour of the treatment ( - 8  mm Hg). The 
change in intra-ocular pressure over the first two hours was
statistically significant compared to the control group of eyes. (p <
0 .001) .
This decrease in intra-ocular pressure was sustained over the 2 
1 2  hour period of the study with a final intra-ocular pressure reading 
of 24.1 mm Hg. The contrast between the treated and the control group 
of eyes was statistically significant over the 2 - 1 2  hour periods of 
the study (p < 0 .0 0 0 1 ).
Table 21: This table documents the mean (+ S.D.) intra-ocular
pressure change in the (-) timolol maleate treated and 
control eyes over the 1 2  hr period of the study.
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Time Timolol Maleate Diurnal
Treated eyes S.D. Control eyes S.D.
(mm Hg) (mm Hg) (mm Hg) (mm Hg)
0 34.3 6.9 27.6 2.9
15 mins 29.7 4.4 N/T
30 mins 27.2 7.6 N/T
45 mins 26.7 6 . 1 N/T
60 mins 25.7 7.1 27.3 5.4
1  1 / 2  hrs 25.4 7.3 N/T
2 hrs 24.2 8 . 0 28.8 6 . 1
3 hrs 23.8 6 . 0 27.0 6 . 2
4 hrs 23.4 8 . 6 25.4 3.6
5 hrs 23.6 7.1 24.9 7.7
6 hrs 23.5 7.5 25.9 7.8
7 hrs 2 1 . 6 5.1 27.8 6.4
8 hrs 19.4 8.4 28.2 6.5
9 hrs 2 2 . 6 9.5 28.1 3.9
1 0  hrs 21.9 8 . 2 29.7 5.2
1 1  hrs 24.0 8.4 30.2 5.3
1 2  hrs 24.1 6.3 29.9 4.3
Table 21: Mean intra-ocular pressures (+ S.D.) of the
maleate treated and control eyes over 1 2  hours. 
N/T = Not treated.
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Figure 47: Effect of 1 drop of 0.5% (-) timolol maleate (Timoptic)
on intra-ocular pressure in buphthalmic eyes. Each point 
represents the mean I.O.P. of 5 rabbit eyes.
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Figure 48:
This figure documents the consensual effect of (-) timolol maleate 
on the untreated eyes. As indicated mean intra-ocular pressure dropped 
20% from 24.5 to 19.5 mm Hg in this group of eyes over the first hour. 
Specific contrast between the treated eyes and the untreated eyes was 
not statistically significant (p <0.30) confirming systemic absorption 
with a consensual effect on the untreated second eyes. Over the 2 - 1 2  
hour period of the study the drug treated I.0.P.'s were significantly 
higher than the I.0.P.'s in the untreated eyes (p < 0.0001). This was 
due to much higher initial mean pressures in the drug treated group of 
eyes (See discussion).
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Figure 48: Consensual effect of (-) timolol maleate.
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Figure 49:
This figure documents the effect of one 50 ul drop of 0.5% topical 
betaxolol hydrochloride (Betoptic) on bupthalmic rabbit intra-ocular 
pressure. As indicated mean intra-ocular pressure dropped 23.3% from 
31.7 mm Hg to 24.3 mm Hg after 1 hour (-7.4 mm Hg). The initial change 
in intra-ocular pressure over the first 2 hours of the study was 
statistically significant when compared to the control group of eyes (P 
< 0.01).
The drop in intra-ocular pressure was sustained over the 2 - 12
hour period of the study with the final mean intra-ocular pressure 
reading 21.6 mm Hg. The contrast between the treatment and control 
group of eyes was statistically significant over this period of time (P 
< 0.0001).
Table 22: This table documents the mean (+ S.D.) intra-ocular
pressure's in the betaxolol hydrochloride treated and 
control group of eyes over the 1 2  hour period of the 
study.
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Figure 49: Effect of 1 drop of 0.5% betaxolol hydrochloride on
Buphthalmic rabbit intra-ocular pressure.
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Time LI 32-468
Treated eyes S.D. Control eyes S.D.
(mm Hg) (mm Hg) (mm Hg) (mm Hg)
0  min 31.7 6 . 2 26.2 5.6
15 min 26.8 4.5 N/T
30 min 26.1 7.4 N/T
45 min 24.6 6.9 N/T
1  hr 24.3 4.4 N/T
1  1 / 2  hrs 22.7 5.4 25.1 6 . 2
2 hrs 23.5 5.6 27.4 7.1
3 hrs 2 2 . 1 6 . 6 25.9 6.5
4 hrs 20.3 5.1 26.2 6 . 2
5 hrs 2 2 . 6 4.8 24.5 9.2
6 hrs 2 2 . 1 4.5 24.9 7.0
7 hrs 23.9 6.9 26.3
CM
8 hrs 2 1 . 2 2.5 27.9 7.2
9 hrs 2 1 . 2 2 . 2 28.1 4.7
1 0  hrs 21.4 3.5 28.4 5.0
1 1  hrs 22.9 3.9 27.7 4.7
1 2  hrs 2 1 . 6 2.4 27.8 7.2
Table 22: Mean intra-ocular pressure's (+ S.D.) in the Betaxolol
HC1 and control treated group of eyes.
N/T = Not tested.
Figure 50:
This figure indicates that 0.5% betaxolol hydrochloride was 
systemically absorbed and had a consensual effect on the untreated group 
of eyes. This drug dropped mean intra-ocular pressure in the untreated 
eyes from 30 mm Hg to 22 mm Hg within 1 hour of treatment. There was no 
statistical difference between the treated and untreated eyes over the 
0-2 hr period of the study (P < 0.06). Over the 2 - 1 2  hour period 
there was no statistical difference between the intra-ocular pressure in 
the drug treated versus the untreated group of opposite eyes (P < 0.30)
indicating a long term consensual effect (See discussion).
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Figure 50: Consensual effect of 1 drop of 0.5% betaxolol
hydrochloride.
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DISCUSSION
I. Discussion of Intra-ocular Pressure Recovery Rate (Aqueous Humour
Index) Results
The radioligand experiments reported in the developments section of 
this study support the view that beta - 2 adrenoceptors exist in ciliary 
processes. The next goal of this project was to determine whether Beta- 
2 blockers inhibit aqueous production. Using the I.O.P. recovery rate 
technique we report that beta - 2 blockers do inhibit production of this 
fluid.
Even though the I.O.P. recovery rate technique is an indirect 
method of measuring aqueous production, it is generally accepted as a 
good model (Chiou, 1982; Chang et al., 1985). This test depends on the 
intra-vascular hyperosmotic effect of saline. This hypertonicity causes 
ocular dehydration with passage of water from the eye via the semi 
permeable membranes of the blood-aqueous barrier (Flood, 1986). 
Varielles and Lotti have indicated that rehydration of the eye is mainly 
a function of aqueous production which can be monitored by measuring the 
intra-ocular pressure recovery rate (Varielles and Lotti, 1981).
A major criticism that can be leveled at this particular test model 
is that it is an indirect measurement of aqueous production. 
Advantanges of this technique include:
1) It is a simple in vivo technique to preform.
2) It is an inexpensive method of measuring aqueous production 
compared with the other techniques such as fluorophotometry 
(Coakes 1978).
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3) It is non-injurious to the test animal eye and has no
permanent ill effect on the experimental animals. Some of the 
other techniques used to study aqueous humour production and
flow commonly involve invasive proceedures and/or the use of
radioactive tracers (Stamper et al., 1986; Jones and Maurice,
1978; Seidehamel and Duncan, 1974).
As indicated on table 17, two of the beta-2 blockers namely IPS 339 
and LI 32-468 inhibited aqueous production by 45% and 42% respectively. 
Timoptic and ICI 118551 inhibited IOP recovery by 27% and 22% 
respectively. Betaxolol hydrochloride only slightly inhibited aqueous 
humour recovery. It is interesting to note however, that all the drugs 
had a consensual effect on the buffer treated second eyes, thereby 
partially invalidating the comparisons between the drug treated and 
buffer treated eyes. This consensual drug effect however was predicted 
before the study commenced as it commonly occurs in animals and the 
human situation (Neufeld, 1979; Shin, 1986). Why it should occur
however is not clear; various theories exist. 1 ) it could be due to 
systemic absorption from the treated eye or gastrointestinal tract (via 
the nasolactrimal duct) with blood born delivery of drug to receptors 
in the second eye (Woodward et al, 1987). 2) It could be due to
systemic absorption producing a systemic hypotensive effect which 
secondarily decreases I.O.P. (Novack, 1987). 3) It could be due to
neural mechanisms, wherein a decrease in I.O.P. in one eye results in 
reflex lowering of I.O.P. in the contralateral eye (Novack, 1987). 4)
Finally it could be due to central effects (Liu and Neufeld, 1985). To 
obviate against this consensual phenomenon normal IOP recovery rate data
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was collected in the same group of rabbits (control group) before the 
drug experiments were started. When the results of the drug treated 
eyes are compared with this control group, the overall results remain 
the same that is; beta-2 blockers inhibit IOP recovery rate more 
potently than non-specific and beta-1 specific drugs. As indicated in 
Table 17 IPS-339 and LI 32-468 inhibited I.O.P. recovery by 6 6 % and 61%. 
ICI 118551 inhibited recovery by 59%. (-) timolol maleate and betaxolol
hydrochloride inhibited recovery by 50% and 42% respectively.
As indicated in the developments section betaxolol HC1 bound more 
potently to ciliary process beta-adrenoceptors than Racemic timolol 
maleate. (-) timolol maleate however is used to treat glaucoma and was 
the form used in this section of the study. It is therefore not 
surprising that betaxolol hydrochloride had slightly less effect than (- 
) timolol maleate on IOP recovery rate (42% and 50% respectively).
It is difficult to compare the results documented in this section 
of the study with other published data. As previously indicated this 
study is the first to report the effect of beta - 2  blockers on aqueous 
humour production Varielles and Lotti, however reported the effects of 
1% (-) timolol maleate ointment on IOP recovery in normal rabbits.
These authors noted that 1% (-) timolol maleate ointment reduced IOP 
recovery rate by 40% (Varielles and Lotti, 1981). The slope of the 1% 
(-) timolol maleate IOP recovery curve reported by these authors was 
0.077 mm Hg/min^. The slope of the 0.5% (-) timolol maleate IOP
o
recovery rate line in our study was similar (0.070 mm Hg/min ). We 
noted a 26.8% difference between the drug v s . buffer group while 
Vareilles et al reported a 40% difference between their two groups. The
reason Varielles and our study report different recovery rates is
probably due to the different absorption properties and hence consensual
effects between drops and ointment.
It is interesting to note that the control data in both studies was
o
similar. Varielles and Lotti reported a 0.110 mm Hg/min slope for the
o
IOP recovery rate, while we noted a 0.14 mm Hg/min IOP recovery rate in 
our experimental control group.
As indicated in the methods and materials section of this study, 
the IOP recovery rate experiments were started approximately 50 min. 
after topical application of drug. It is therefore very interesting to 
note the effect of the various drugs on normal rabbit IOP. As indicated 
in the appropriate graphs, topical IPS-339, LI 32-468, (-) timolol
maleate, ICI 118551 and betaxolol HC1 all produced a drop in IOP of less 
than 1 mm Hg, 50 minutes after installation of 100 ul of appropriate 
drug. This data strongly supports the view that normal rabbit eyes are 
a poor model for studying the effects of drugs on rabbit IOP (Liu et
al., 1984, Varielles, 1977, Bonomi et al., 1979).
In conclusion the results of this section of the study confirm that 
topical beta blockers inhibit aqueous humour production. Furthermore, 
the results indicate for the first time that beta - 2 blockers inhibit 
aqueous production more potently than beta - 1  and non-specific beta 
blockers. These results support the view that beta-2 adrenoceptors 
control aqueous production. The results also suggest that beta-2 
blocker may lower I.O.P. in glaucomatous eyes via inhibition of aqueous 
production (see next section).
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II) Discussion of Results on buphthalmic Rabbits.
The purpose of this study was to determine whether beta-2 blockers 
lower I.O.P. in glaucomatous rabbit eyes. As buphthalmic rabbits 
respond to anti-glaucoma drugs in a similar manner to patients with 
primary open-angle glaucoma (Variellas 1985, Auriccho and Wistrand, 
1959) we felt such a study may indicate the potential clinical
usefullness of this class of drug.
The results of the study were encouraging. As indicated in the
results section, the beta-2 blockers IPS 339, LI 32-468, and ICI 138551
all significantly lowered buphthalmic rabbit IOP within one hour of 
treatment with a 50 ul drop of the appropriate drug. The mean drop in 
intra-ocular pressure was 23%, 21.8% and 16.6% respectively.
Furthermore, all three drugs lowered intra-ocular pressure for the 
duration of the study namely 12 hours. These results are particularly 
encouraging when considered in relation to present day medication for 
primary open-angle glaucoma. Topical (-) timolol maleate
(Timoptol/Timoptic) and betaxolol HCL (Betoptic) are the major drugs 
used to treat primary open-angle glaucoma in both Europe and North 
America (Novack, 1987, Leopold and Duzman, 1986; McGlaughion and Chiou,
1985). The data derived from this section of the study indicates for 
the first time that beta-2 blockers lower buphthalmic rabbit I.O.P. in a 
similar fashion to drugs presently used to treat P.O.A.G. Beta-2 
blockers may therefore lower intra-ocular pressure in humans with POAG 
with less side effects than non-specific and beta-1 blockers (See 
later).
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The only drug that has previously been studied in the
buphthalmic rabbit eye is (-) timolol maleate. Varielles et al., 
reported a 24.2% drop in mean buphthalmic rabbit IOP 1 hour after a 100 
ul eye drop of 1% (-) timolol maleate (Varielles et al., 1980). These 
authors also reported an effect on I.O.P. 5 hours later. As indicated 
above our results are very similar (a 23.3% drop at 1 hour) even though 
we used a smaller drop size (50 ul) and lower dosage (0.5%).
It is difficult to compare drug potencies on buphthalmic rabbit 
IOP's. As indicated in the results section, even though the same 
rabbits were used to test each drug, mean starting IOP levels differed 
from day to day. For example, the mean starting IOP level was 34.3 
mm/Hg at 7 a.m. on the morning when (-) timolol maleate was tested, 
while it was 24 mm/Hg at the same time of day when ICI 118551 was 
tested. It is well known that the higher the initial IOP, the greater 
the drop in IOP after treatment (Lotti et al., 1984). This could 
explain why ICI 118551 had less of a short-term effect on IOP them the 
other beta-2 drugs. Despite this our results support the view that all 
3 beta-2 blockers should be considered for trial in patients with POAG 
if ocular toxicological studies prove negative.
As indicated above one problem with using buphthalmic rabbits is 
the fact that the IOP varies from day to day. This fact makes 
interpretation of the control and experimental data difficult. For 
example, the diurnal curves performed before each drug was tested 
revealed initial IOP readings ranging between 24-28 mm/Hg. However, 
initial IOP readings on the day of the tests ranged between 24-34 mm/Hg. 
Despite these differences statistical analysis was possible between the
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drug and control eyes.
As indicated in the results section, all the topical drugs tested 
produced profound consensual pressure reducing effects. This was 
particularly evident in the (-) timolol maleate study. In this study 
final mean I.O.P.'s were lower in the untreated eyes than the treated 
eyes. Clearly this was due to a combination of factors nl systemic 
absorption of drug and lower initial I.O.P.'s in the untreated group of 
eyes. This consensual effect has previously been documented in both 
animals and humans with glaucoma (Variellas et al., 1977; Woodard et 
al., 1987; Zimmerman and Kaufman, 1977; Shin 1986). Why the consensual
effect occurs is not clear (Lotti, 1984). The various theories have 
been discussed in section I of this discussion.
The consensual effect together with the assymetry of pressures in 
rabbits with buphthalmos makes statistical comparison between the two 
eyes impossible. As a result Variellas et al., in their drug studies on 
buphthalmic rabbits used initial IOP as the control level and IOP at 
various time intervals thereafter as the comparison levels (Variellas et 
al. , 1980). Clearly, a problem exists with this method, that is it
presupposes that change in I.O.P. is only due to drug effect. This 
method neglects diurnal changes in I.O.P. and is therefore potentially 
misleading. Even though diurnal curves varied in our study, we used 
diurnal curve controls rather than initial I.O.P.'s or second eyes for 
reasons described above.
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Some of the problems we experienced using the buphthalmic rabbit
model are noted below:
1) Buphthalmic rabbits are not readily available and have to be 
specially bred.
2) The gene for buphthalmos is semi lethal and therefore the
rabbits do not survive well unless carefully looked after.
3) Examination of the fundi of these animals is not possible due 
to the cloudy cornea. Therefore it is not possible to conduct
ophthalmoscopic studies to determine whether a drug under investigation 
prevents optic nerve damage.
4) The raised intra-ocular pressure varies widely between
individual rabbits and from day-to-day in the same rabbit eye.
5) The glaucoma although usually bilateral is often assymetric.
Despite these problems, for reasons previously stated, we believe
that the buphthalmic rabbit model remains a useful model for studying
anti-glaucoma drugs.
In conclusion, this section of the study supports both the in vitro 
binding data and in vivo I.O.P. recovery rate experiments that beta-2 
adrenoceptors control aqueous production and I.O.P. Furthermore, the 
data derived from this section of the study confirms that beta - 2  
blockers lower I.O.P. in buphthalmic rabbits which strongly suggests
that this class of drug may lower I.O.P. in patients with P.O.A.G.
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Ill. Review of Evidence for and against beta-adrenoceptor involvement in
Aqueous Production
The data presented in this thesis supports the evidence that beta-2 
adrenoceptors play an important role in aqueous production and intra­
ocular pressure control.
1) Evidence to support beta adrenoceptor involvement in aqueous 
production and IOP control.
As indicated earlier in this thesis, the ciliary processes are well 
innervated with sympathetic fibres (Ehinger 1964; Ehinger 1966; Matsuka 
1981). Furthermore, it is now known that aqueous humour contains all 
three catecholamines (Cooper and Constable, 1984; Trope and Rumley, 
1985; Trope et al., 1987). The exact origin of human aqueous 
catecholamines however remains uncertain. These amines may be derived 
from two different sources; 1) They may be derived from overflow from 
sympathetic nervous stimulation to receptors in the iris ciliary body 
diaphragm or 2) they may arise from an overflow from plasma. There is 
clinical evidence implicating circulating epinephrine in the production 
of aqueous humour (Topper and Brubaker, 1985). No matter the exact 
source of origin of aqueous catecholamines it seems likely that 
adrenaline exerts its effects on the ciliary processes via beta- 
adrenoceptors.
Ample evidence now exists that ciliary epithelium responds to beta 
(in particular beta-2) stimulants by producing cyclic AMP (Neufeld et 
al., 1972; Sutherland and Robinson, 1966; Cepelik and Cernohorsky, 1981; 
Nathanson, 1980; Nathanson, 1981; Elena et al., 1984). Evidence also 
exists that cyclic AMP is not produced by the ciliary processes in the
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presence of beta blockers (Neufeld, 1979). This data plus in vitro 
fluid flow studies on rabbit ciliary epithelium (Green and Mayberry, 
1983) also supports the view that beta-2 adrenoceptors control aqueous 
production via the adenylate cyclase system.
In addition to the above evidence, there is also in vivo evidence 
to support the view that ciliary process beta stimulation increases 
aqueous humour production. In 1970, Bill showed that intracameral 
isoproterenol (beta stimulant) increased aqueous humour production by 
30% in monkey eyes (it also increased outflow facility by 55%), and that 
the non-specific beta blocker, propranolol, blocked this stimulatory 
effect (Bill, 1970). Bill's work has recently been confirmed in humans. 
Fluorophotometric observations by Townsend and Brubaker, have shown 
that adrenaline increases aqueous production (Townsend and Brubaker, 
1980; Brubaker, 1986). Recently, Lee et al, indicated that it is the 
beta effect of adrenaline that increases aqueous humour production. Lee 
et al reported a 19% increase in aqueous humour production after the 
topical administration of adrenaline. This increase in aqueous 
production was maximal when the alpha effect of adrenaline was blocked 
with an alpha adrenergic blocker (Lee et al., 1983). Higgins and 
Brubaker reported that (-) timolol maleate blocked the aqueous 
stimulating effect of adrenaline (Higgins and Brubaker, 1980). Higgins 
and others have interpreted this data to mean that ciliary process beta- 
adrenoceptors control aqueous production (Potter, 1981; Higgins and 
Brubaker, 1980). We believe our binding data and animal experiments 
support this view and extend this knowledge to involve beta - 2  
adrenoceptors as the major receptor subtype controlling aqueous
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production and I.O.P.
2) Evidence against beta-adrenoceptor control of aqueous 
production and I.O.P.
Despite the above published evidence some workers continue to 
believe that beta-blockers and beta stimulants do not exert their 
aqueous humour influencing effects via beta-adrenoceptors (Schmitt, 
1981; Chiou, 1985; Varielles et al., 1977 and Bonomi, 1979). These
workers often base their theories on animal work much of which has been 
performed using unsatisfactory animal models such as the water or 
glucose loaded rabbit (Lotti et al., 1984). As previously discussed, 
such models do not allow for accurate interpretation regarding receptor 
mechanisms involved in aqueous production.
An aspect of this subject that requires clarification is the role 
of adenylate cyclase on aqueous production. As previously indicated 
beta adrenergic stimulants exert their effect by stimulating beta 
receptors which in turn stimulate cyclic AMP production. Cyclic AMP is 
not produced by the ciliary processes in the presence of beta blockers. 
These facts all strongly support the theory as previously indicated that 
beta adrenergic stimulants and endogenous catecholamines act by 
stimulating beta-adrenoceptors and cyclic AMP to increase aqueous humour 
production. To test this hypothesis, Sears reported the effects of 
cholera toxin on the ciliary epithelium (Sears, 1981). Cholera toxin 
stimulates adenylate cyclase activity in many tissues. Sears reported 
that cholera toxin stimulated cyclic AMP production in rabbit eyes, but 
this production was associated with a decrease in both intraocular 
pressure and aqueous humour production. This surprising finding appears
inexplicable until one carefully reviews the original article in which 
this report appeared (Sears, 1981). Sears clearly indicated that the 
ciliary epithelial cells were pathologically swollen on light microscopy 
as a result of the cholera toxin administration. It is therefore not at 
all surprising that aqueous production (secretion) decreased with use 
of this toxin. Clearly, cells were capable of producing cyclic AMP but 
were so damaged as to be unable to secrete aqueous humour into the 
lateral intracellular spaces. Sears continues to believe that cyclic 
AMP decreases aqueous humour production (Caprioli and Sears, 1983; Sears 
and Condo, 1986). Sears has also attributed the claimed IOP lowering 
effect of Forskolin, a potent adenylate cyclase activator, to a decrease 
in aqueous humour production (Caprioli and Sears, 1983). The effect of 
Forskolin on aqueous production and I.O.P. however remains controversial 
(Potter et al., 1985). Brubaker and others have been unable to confirm 
an effect of Forskolin on human aqueous production and I.O.P. (Brubaker, 
1986). Despite the controversy regarding the role of Forskolin on 
aqueous production and intra-ocular pressure control, Sears has proposed 
a new theory regarding aqueous production. He believes that ciliary 
epithelium cell polarity is reversed due to the invagination that occurs 
during embyrological development of the eye. With activation of 
adenylate cyclase, cyclic AMP activates intracellular protein kinase to 
stimulate fluid movement from the base of the cells to the apical 
surfaces of the non-pigmented epithelium. Sears goes on to suggest that 
fluid then moves via 'intra-apical ciliary channels' with eventual 
transudation of fluid across the pigment epithelium away from the 
posterior chamber. This theory has no scientific basis at present and
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neglects the fact that the junctions of the cells i.e., between the 
pigmented and non-pigmented cells, are closed by dense junctional 
complexes (Cole, 1977). Sears agrees that considerable work is 
necessary to test this hypothesis (Sears, 1986). The proposed theory 
that beta-adrenoceptor stimulation activates adenylate cyclase leading 
to increased aqueous production remains a much more plausable theory.
One aspect of aqueous humour production that still requires further 
el ucidation is the all important relationship between cyclic AMP and 
ciliary processes membrane bound NA: K ATPase. Sodium pottasium ATPase
is still believed to be the major enzyme controlling aqueous secretion. 
An in vitro study to determine the effect of cyclic AMP on ciliary 
process sodium pot ,asium APTase would significantly improve our 
knowledge regarding the physiology and pharmacology of secretion of 
aqueous humour and I.O.P. control (Rushton, 1983).
Another aspect so far not discussed is the possible role of beta 
adrenergic agents on choroidal and ciliary processes vasculature. There 
are some workers who believe that beta blockers may qffect aqueous 
humour production and I.O.P. via a vascular or filtration mechanism of
action (Smith, 1987; Langham and Craigie, 1979; Potter, 1981). It is
known that many blood vessels contain beta2 vasodilatory receptors 
(Breckenridge, 1983). Malik has reported that isoprenaline increases 
uveal perfusion in pigs (Malik, 1976). This finding suggests that beta- 
adrenoceptors may exist in uveal vasculature. If so, beta blockers 
could theoretically block uveal beta - 2 vasodilatory receptors producing 
vasoconstriction as occurs in the peripheral circulation (Breckenridge,
1983). Confirmatory Evidence to support this theory is however non-
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existant (Lotti et al., 1984).
The fact that betaxolol hydrochloride lowers I.O.P. in human eyes
has further stimulated speculation regarding controlling receptor
mechanisms (Novack, 1987). In 1984 we suggested that if an adequate
concentration of a relative beta- 1  selective agent is achieved in the
anterior chamber, relative beta- 1  selective blockers will block ciliary
process beta-2 receptors (Trope and Clark, 1984). As indicated in table
-  615 for betaxolol hydrochloride is 6.39 x 10 M. Phillips and others 
have reported that within 1 hour after topical instillation in humans 
and animals the concentration of 1 drop of 0.5% (-) timolol maleate is 
1.2 x 10"^ M (Phillips, 1985; Ross et al., 1979; Schmitt, 1980). If one 
assumes that betaxolol hydrochloride is lipid soluble enough to achieve 
aqueous humour concentrations similar to (-) timolol maleate, it seems 
reasonable to suggest that ciliary process beta - 2 adrenergic blockade 
will occur with topical instillation of this beta - 1  antagonist in human 
eyes (Novack, 1987).
Other less plausible theories regarding control of aqueous 
production have been suggested, but definite proof regarding these 
theories is lacking (Potter, 1984; Phillips, 1987; Liu and Cho, 1981; 
Gregory, 1981; Yorio, 1985).
In conclusion .^believe that the work reported in this thesis 
supports the traditional theory of beta-adrenoceptor control of aqueous 
production. Further work however is required to determine:
1) Whether aqueous humour can flow from the posterior chamber to 
ciliary processes vasculature as proposed by Sears.
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2) The role of Na:K ATPase in aqueous production and the 
relationship between Forskolin, cyclic AMP and Na:K ATPase.
3) Whether beta-2 receptors exist in uveal tissue.
Answers to the above 3 questions will provide valuable insight into 
the physiology of aqueous production and I.O.P. control.
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IV. Systemic Side-Effects of Non - Specific and Beta-1 Blockers
In 1978 (-) timolol maleate was introduced to treat POAG. (-)
timolol maleate effectively controls I.O.P. for several years (Steinart 
et al., 1981; Strempel, 1982; Neilson, 1982; Villies, 1983 and McLaughin 
and Chiou, 1985). There is a tendency for I.O.P. to drift upward from 
the original maximum hypotensive effect overtime but seldom enough to 
warrant discontinuing (-) timolol maleate treatment (Steinart et al., 
1981). In upio 25% of cases of P.O.A.G. additional drugs are needed to 
maintain satisfactory I.O.P. control (Gillis et al., 1983).
Topical (-) timolol maleate can produce significant local and 
systemic side effects. In fact (-) timolol maleate is. the drug most 
frequently reported to the national registry of drug induced ocular 
side-effects in the U.S.A. (Van Buskirk and Fraunfelder, 1984). By far 
the most important and serious side-effects are respiratory and 
cardiovascular events attributed to this drug. By November 1986, over 
450 case reports of serious and even fatal respiratory and 
cardiovascular events had been reported to the Food and Drug 
Administration in the U.S.A. (Neilson et al., 1986). By 1986 product
labelling in the U.S.A. contained a warning in bold face type that "The 
same adverse actions found with systemic administration of beta- 
adrenergic blocking agents may occur with Topical administration" 
(Neilson et al., 1986). Shell reported that approximately 80% of
topically administered eye drop volume drains through the nasolacrimal 
duct and is systemically absorbed (Shell, 1982). Neilson has reported 
that beta-adrenergic antagonists administered in eye-drop form may not 
undergo first-pass metabolism and therefore may behave like an
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intravenous drug dose resulting in serious respiratory and 
cardiovascular side effects (Neilson et al., 1986). Other severe
adverse effects reported with topical (-) timolol maleate eyedrops 
include; psychotic reactions, impotence, loss of libido, depression, 
personality changes and transfer in breast milk with apnoea in babies 
(Van Buskirk, 1980 and Munroe, 1985).
The Pharmaceutical industry have responded to these reports by 
trying to develop topical beta-blockers with decreased systemic side- 
effects. In 1982, Berrospi and Leibowitz, reported that betaxolol HC1 
lowered I.O.P in patients with glaucoma (Berrospi and Leibowitz, 1982). 
This drug was introduced into the North American and U.K. markets for 
use in P.O.A.G. in 1986. Betaxolol HC1 binds more potently than 
propranolol to beta- 1  receptors in cardiac tissue and has been shown to 
be able to decrease cardiac output significantly on systemic 
administration (Giudicelli et al., 1980).Initial reports suggested that 
betaxolol HC1 was virtually as efficatious as (-) timolol maleate in 
lowering I.O.P. and had less cardiovascular and respiratory side-effects 
than (-) timolol maleate (Berry, 1984; Schoene et al., 1984). Recent 
data however indicates that betaxolol HC1 does not lower I.O.P. as 
effectively as (-) timolol maleate (Allen et al., 1986) and does indeed
produce significant systemic side-effects such as bronchospasm, heart 
failure and depression (Ball, 1987; Harris et al., 1986 and Orlando,
1986). In fact, 56 cases of serious adverse events have recently been 
reported to the F.D.A. (Neilson and Kuritsky, 1987).
Even though, betaxolol HC1 is essentially a beta-1 blocker, as 
indicated on Table 14 this drug binds potently to beta-2 adrenoceptors
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in the ciliary processes (K^ = 6.39 x 10" M) . In fact it binds more 
potently than (+) timolol maleate to these receptor sites (K^ = 1 . 4 0  x 
10" 5 M ) . As previously indicated it is therefore not surprising that 
this drug lowers intra-ocular pressure in humans with P.O.A.G. 
Furthermore, our data shows that betaxolol HC1 significantly inhibits 
rabbit aqueous humour production and lowers intra-ocular pressure in 
buphthalmic rabbit eyes. However, this drug did not bind as potently as 
the beta-2 antagonists to ciliary process beta-receptors (Table 15) nor 
does it inhibit aqueous production as potently as the three beta - 2  
blockers tested (Table 17).
In conclusion topical betaxolol hydrochloride is a useful drug in 
older patients with P.O.A.G., but should be used with caution if these 
patients suffer from cardiovascular or respiratory disease. This drug 
has relatively few advantages over topical (-) timolol maleate.
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V. The potential role for beta-2 blockers in P.O.A.G.
As indicated above present medical management of P.O.A.G. is far 
from perfect, as both non-specific and beta - 1  specific blockers are 
associated with significant local and systemic side-effects.
There are as yet no published reports on the effects of topical 
Beta-2 blockers in patients with glaucoma. A trial of topical beta-2 
blockers for use in P.O.A.G. is indicated for the following reasons;
1 ) beta - 2 blockers bind potently in vitro to beta - 2 receptors in 
ciliary processes (this thesis),
2) Topical beta-2 blockers significantly inhibit aqueous production 
in rabbit eyes (this thesis),
3) Topical beta-2 blockers lower intra-ocular pressure in 
bupthalmic rabbit eyes (this thesis),
4) Beta-2 blockers bind more potently and inhibit aqueous 
production more potently than non-specific and beta - 1  specific blockers 
(this thesis). Beta-2 blockers may therefore be more efficacious than 
non-specific and beta-1 blockers in patients with P.O.A.G.
5) In view of the relative cardio-protective effects of beta-2 
blockers, the development of such drugs could lower the incidence of 
cardiovascular side-effects in elderly patients with P.O.A.G. The 
relative cardio-protective effect of beta - 2 antagonists may also have 
beneficial implications regarding optic nerve perfusion in patients with 
P.O.A.G.
Two of the beta-2 drugs reported in this thesis have undergone 
extensive animal studies to determine their safety. Both ICI-118551 and 
Sandoz LI 32-648 are considered safe by the drug companies for clinical
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trials. In view of the binding potency of Sandoz LI 32-648 (K^ =
Q
10 M) it would seem that this drug would be ideal for clinical 
in patients with P.O.A.G.
2.91 x 
trials
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